Pulmonary surfactant inhibition following cardiopulmonary bypass by Phang, P. T.
CENTRE FOR NEWFOUNDLAND STUDIES 
TOTAL OF 10 PAGES NLY 
MAY BE XEROXED 
(Without Author's Permission) 

·. 


PULMONARY SURFACTANT INHIBITION 
FOLLOWING 
CARDIOPULMONARY BYPASS 
BY 
© P.T. PRANG, M.D. 
A THESIS SUBMITTED TO THE SCHOOL OF GRADUATE 
STUDIES IN PARTIAL FULFILLMENT OF THE 
REQUIREMENTS FOR THE DEGREE OF 
MASTER OF SCIENCE 
FACULTY OF MEDICINE 
MEMORIAL UNIVERSITY OF NEWFOUNDLAND 
ST. JOHN'S, NEWFOUNDLAND, JUNE, 1984 
i 
Abstract 
Following cardiopulmonary bypass (CPB) patients exhibit 
varying amounts of pulmonary dysfunction. This study 
examined the possibility that plasma which leaked into the 
alveoli could cause a reduction in the ability of pulmonary 
surfactant to reach very low surface tension (surfactant 
inhibition). The possibility that CPB could cause an 
increase in any component of plasma which might inhibit 
surfactant function was also examined. Plasma from adult 
and child patients was tested. Surfactant was prepered from 
pig lungs. Surfactant function was measured as ability to 
lower surface tension on a Langmuir-Wilhelmy balance. 
Plasma from normals and CPB patients before and after bypass 
was mixed with pig surfactant and tested on the balance. 
The surface load of surfactant was constant while the amount 
of plasma was varied. 
Plasma from normals, adult patients and child patients 
inhibited the surfactant. Serum, fibrinogen, albumin and 
globulins also inhibited surfactant in this assay. The 
amount of inhibition was proportional to the amount of 
protein added. No increased inhibition was seen in 
post-bypass vs. pre-bypass samples in adults or chil4ren. 
Inhibitor(s) are present in normal plasma and do not appear 
ii 
to be increased by the bypass procedure. It is possible 
that plasma components entering airspaces through leaking 
lung membranes may inhibit surfactant from proper function, 
and may contribute to lung collapse and edema seen in the 
ARDS of any etiology. 
The nature of the inhibition was examined by 
characterization of the inhibitor and by studying models of 
protein-surfactant interaction on the surface balance. 
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Chapter 1 
Introduction 
1.1 Overview 
This thesis addresses the problem of lung surfactant 
dysfunction following surgery in which cardiopulmonary 
bypass (CPB) is employed. 
with consideration of: 
The literature has been reviewed 
1. lung surfactant, under the headings 
surfactant function in health 
alveolar and surfactant structure 
surfactant composition, synthesis and turnover 
surfactant component function and physical 
properties, 
2. acute respiratory failure, under the headings 
respiratory distress syndrome (RDS) of the newborn 
adult respiratory distress syndrome (ARDS) 
respiratory distress following CPB 
surfactant and ARDS, and 
3. the hypothesis that lung surfactant may be inactivated 
by inhibitors from plasma which may leak into the 
alveoli through lung membranes damaged during acute 
lung injury, under the heading 
2 
surfactant inhibitors including their association 
with cardiopulmonary bypass. 
It is considered that an essential feature of pulmonary 
surfactant is its ability to lower the surface tension at 
the alveolar air-water interface to very low values. The 
phrase ''inhibition of surfactant" and related phrases will 
be used throughout this thesis to mean prevention of the 
ability of surfactant to reach low surface tension during 
compression of a surfactant monolayer in a Langmuir-Wilhelmy 
balance. 
1.2 Surfactant Function in Health 
Surfactant is found in the acellular lining layer of the 
alveoli. It has the ability to lower surface tension 
(Pattle~ 1955~ 1965; Clements 1956, 1957~ 1962; Clements, 
Hustead~ Johnson & Gribetz~ 1961). This property 
counteracts the tendency to alveolar collapse, facilitates 
opening of fluid-filled alveoli~ increases lung compliance, 
decreases work of breathing~ and decreases transalveolar 
hydrostatic forces forming pulmonary edema (Notter & Morrow~ 
1975; Notter, Finkelstein & Taubold, 1983; Bredenberg, 
Paskanik & Nieman, 1983; Beck & Lai-Fook, 1983). Open 
alveoli facilitate gas exchange by improving oxygenation and 
CO excretion. It has been postulated that the lining layer 
2 
of the lung aids the clearance of particulate matter and the 
suppression of invading microorganisms (Schwartz & 
Christman~ 1979; Schlimmer~ Austgen & Ferber~ 1983). 
3 
There is both a functional and structural basis for putative 
surfactant activity. Mammalian lungs were found to contain 
this very surface active material (Pattle, 1955; Clements, 1956) 
Pattle (1955) observed the highly stable characteristics of 
lung edema foam. Clements (1956) observed low surface 
tension and hysteresis of extracts of lung minces tested on 
the surface tension balance. These low surface tensions 
corresponded to calculations made from pressure-volume 
curves of inflated lungs (Brown, 1957; Clements, 1957). 
Lung surfactant deficiency was implicated as the primary 
cause of the respiratory distress syndrome of the newborn 
when extracts of minces from lungs taken from premature 
infants dying with respiratory distress were shown to have 
increased surface tensions on the surface balance (Avery & 
Mead, 1959). Photography demonstrated collapse of terminal 
airways with inflating pressures less than 10 em H 0 in 
2 
excised preterm fetal rabbit lungs with absent surfactant, 
and the beneficial effects of instilling exogenous 
surfactant were seen (Enhorning, 1977a, 1977b). Scanning 
electron microscopy was used to show surface tension effects 
on lung architecture in air-filled, saline-filled and 
detergent-washed lungs (Bachofen, Gehr & Weibel, 1979). 
Surface tension has been measured in situ (Schurch, Goerke 
& Clements, 1976, 1978; Schurch, 1982). Microdroplets of 
fluorocarbon and silicone oils deposited in alveoli formed 
contact angles which were dependent on the surface tension. 
In cat lungs the surface tension was 10 mN/m at 70% of total 
4 
lung volume and was decreased to less than 1 mN/m at 40% of 
total lung volume (=functional residual capacity). At 40% 
of total lung volume the surface tension was stable for 10 
minutes then increased steadily to 9 mN/m over 1 hour. 
1.3 Alveolar and surfactant structure 
The alveoli are the small air-filled sacs at which the 
airways terminate. Their large surface area and thin walls 
facilitate the exchange of gases from air to blood and 
vice-versa. The walls separating the alveoli contain 
endothelial capillaries and basement membranes, an abbreviated 
interstitium, an epithelial basement membrane and the 
continuous alveolar epithelial cell layer (Figure 1-1). 
Adjacent to the alveolar epithelium is the alveolar lining 
layer containing surfactant. 
The structure of the alveolar lining layer has been 
studied using the electron microscope. The acellular 
alveolar lining consists of a uniform 4.2 nm layer at the 
air interface, the surface film, and a heterogeneous layer 
between the surface film and alveolar epithelium, the 
hypophase (Kikkawa, 1970). Freeze-fracture electron 
microscopy has shown the surface film to be smooth and 
without large, globular shadows, suggesting a phospholipid 
layer with no protein (Kikkawa & Manabe, 1978). It has been 
estimated that the surface film is composed of at least 90% 
disaturated phosphatidylcholine, based on the behaviour of 
surface films and lung compliance data (Hildebran, Goerke & 
5 
type I alveolar cell 
alveolus 
interstitium 
endothelium 
alveolus 
Figure 1-1 The alveolar-capillary membranes 
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Clements, 1979; Clements, 1977). The hypophase contains 
structures thought to be lipid aggregates in the forms of 
vesicles, lamellae and lattice-like arrangements called 
tubular myelin (Kikkawa, 1970; Manabe, 1979). Structural 
continuity has been demonstrated on electron microscopy 
between the hypophase structures and the surface film, and 
between the hypophase structures and the lamellar bodies 
being discharged at type II alveolar cell surfaces (Manabe, 
1979; Williams & Benson, 1981). Figure 1-2 depicts the 
putative formation of surfactant in the alveolus. 
The alveolar epithelial cells form a continuous cell layer 
covering the alveolar basement membrane. There are two cell 
types. The cell type covering the majority of the alveolar 
surface is the type I cell. These cells are broad and flat. 
Type II cells are however more numerous (Kuhn, 1982) and are 
cuboidal in shape. The most distinctive cytologic feature 
of the type II cells and the most reliable identifying 
criteria are the secretory organelles called lamellar 
bodies. They consist of a membrane enclosing concentric or 
parallel osmiophilic lamellae on electron microscopy. 
The lamellar bodies begin as multivesicular bodies of the 
Golgi apparatus and endoplasmic reticulum. The mature 
organelle results from accumulation of lipid in the form of 
lamellae and some protein which is associated with residual 
vesicular structures within the lamellar bodies and with the 
outer membrane. No protein-like structures were seen to be 
associated with the interior lamellae on electron microscopy 
air surface film ----------------------------Hl5~-----
hypophase 
Figur e 1-2 
/ 
tubular myelin 
exocytosis of lamellar 
body from 
alveolar type II cell 
Surfactant formation in the alveolus 
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(Kikkawa & Manabe, 1978). The exact site of combining 
protein and lipid is uncertain. The lamellar body 
discharges its contents into the hypophase by exocytosis 
(Askin & Kuhn, 1971). The use of radiolabelled palmitate 
confirmed that lamellar body palmitate was a precursor of 
alveolar lining palmitate (Young, Kremers, Apple, Crapo & 
Brumley, 1981; Jobe, 1979; Jobe, Kirkpatrick & Gluck, 1978; 
Kotas, 1982). 
The control of secretion involves cholinergic and 
B-adrenergic stimulation and prostaglandins, and is not 
fully understood (Dobbs & Mason, 1979; Nicholas & Barr, 
1981; Delahunty & Johnston, 1979; Oyarzun & Clements, 1977, 
1978). Steroids, thyroid hormones, and insulin affect 
synthesis and secretion (Avery, Wang & Taeusch, 1973; 
Liggins, 1969; Liggins & Howie, 1972; Mavis & Vang, 1981; 
Smith & Bogues, 1980). Steroid effects involve a mediator 
from adjacent fibroblasts (fibroblast pneumocyte factor) 
(Smith, 1979). 
1.4 Surfactant: Chemical composition, synthesis and 
turnover 
Samples of the alveolar lining layer are best obtained by 
bronchoalveolar lavage. Extracts of lung minces contain 
more cellular components (Morgan, Finley & Fialkow, 1965; 
Tanaka & Takei, 1983). The alveolar lining layer obtained 
by lavage is diluted many times by the lavage saline, and is 
contaminated by upper airway secretions and by blood 
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components (Reifenrath & Zimmermann, 1973). Centrifugation 
techniques are employed to obtain concentrates which are 
highly enriched in surface activity. It is this material 
which is known as surfactant. A standard protocol for 
preparing surfactant is not yet established. 
The composition of lung surfactant differs slightly 
between mammalian species, and between investigators due to 
differences in processing techniques. As a rough average, 
the percentage composition by weight is 10% protein, 10% 
neutral lipid, and 80% phospholipid. The distinguishing 
feature of surfactant lipid is the high proportion of 
dipalmitoyl phosphatidylcholine (DPPC) and 
phosphatidylglycerol (PG). Such high relative quantities of 
these two lipids are not found in other body tissues. The 
ratio of DPPC to PG, approximately 7:1, is similar in type 
II cells, lamellar bodies and in lavage. This is consistent 
with the view that surfactant originates in the lamellar 
bodies of type II cells (Kikkawa & Smith, 1983). 
review see Keough (1984) and Sanders (1982). 
For a 
The lamellar body of the alveolar type II cell is the 
major storage site for surfactant lipid. DPPC and PG are 
most highly concentrated in the lamellar bodies of the cell. 
Synthesis of the phospholipids occurs primarily in the 
endoplasmic reticulum of the type II alveolar cell 
(Chevalier & Collet, 1972). DPPC may be synthesized 
directly from dipalmitoyl diglyceride and CDP-choline, or by 
acylation of 1-palmitoyl 2-lysophosphatidylcholine by 
10 
pa1mitoyl-coenzyme A (the de- and re-acylation remodeling 
pathway) (Smith & Kikkawa, 1978; Frosolono, Slivka & Charms, 
1971; Ishidate & Wienhold, 1981). A minor route would be 
the transacylation of 1-palmitoyl 2-lysophosphatidylcholine. 
Substrate availability may determine which pathway is used 
in vivo. 
Fatty acids, particularly palmitic acid may be synthesized 
by the type II cells de novo, or may be taken up from the 
pulmonary circulation (Smith & Kikkawa, 1978). 
is derived from the pulmonary circulation. 
The mechanisms of lipid turnover are not fully 
Cholesterol 
established. Hypophase lipid is somehow removed from the 
alveolus. Hyperventilation increases the rate of bulk 
removal (Oyarzun, Clements & Baritussio, 1980). Macrophages 
and mucociliary mechanisms may be involved (Yoneda, 1976; 
Eckert, Lux & Lachmann, 1983; Nicholas & Barr, 1981). DPPC 
may be recycled into the lamellar bodies of type II cells 
(Magoon, Wright, Baritussio, Williams, Goerke, Benson, 
Hamilton & Clements, 1983; Oyarzun et al, 1980; Jobe, 1979; 
Hallman, Epstein & Gluck, 1981). Pinocytic uptake of lipid 
and apoprotein has been demonstrated (Kikkawa & Kaibara, 
1972; Williams & Benson, 1981). 
The hypophase also contains several hydrolytic enzymes 
which may regulate some of the surfactant turnover 
(Orlowski, Orlowski, Kilburn & Lesser, 1981; Hook, 1978). 
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1.5 Surfactant: component function, physical properties and 
structure 
Lung surfactant has the essential physical properties of 
(1) ability to lower surface tension on film compression to 
less than 9 mN/m, (2) rapid adsorption of the surface active 
agent(s), (3) rapid spreading of the surface active agent(s) 
and (4) slow film collapse rates at high surface pressures. 
These abilities should exist in the physiologic temperature 
range about 37 degrees C (Notter & Shapiro, 1981; Taeusch, 
Clements & Benson, 1983; Hawco, Davis & Keough, 1981). 
Studies of the individual components of surfactant have 
application to surfactant replacement in surfactant-
deficient states and the synthesis of such materials. 
Surface film studies on the tension surface balance have 
shown that a DPPC monolayer has the unique characteristic of 
lowering surface tension to approximately zero on film 
compression at 37 degrees C. No other molecular species in 
lung surfactant will approach this surface tension at 37 
degrees C (Clements, 1967, 1973). The effect of temperature 
on liquid condensed-liquid expanded phase transition is 
important with regard to fluidity of the lipid acyl groups 
and ability to achieve a high packing density on film 
compression. The decreased free energy state of high 
packing density is seen as low surface tension. 
Substitution of acyl groups with carbon chains of varying 
lengths and double bonds affects lipid fluid~ty and .Phase 
transition temperatures, and hence ability to attain high 
12 
packing density and low surface tension on film compression 
(Keough, 1984). Slow film collapse rates at high surface 
pressures are also characteristic of pure DPPC monolayers 
and not of other molecular species at 37 degrees C (Keough, 
1984; Goerke & Gonzales, 1981; Hildebran et al, 1979). 
It is generally felt that some selective mechanism allows 
DPPC to form the surface film to account for the low surface 
tensions achievable only by pure DPPC monolayers. This 
mechanism may involve the process of selective lipid 
insertion into the monolayer, selective exclusion (squeeze-
out) from the surface film on compression, or some 
protein-mediated modification of the surface film, analogous 
to the phospholipid exchange proteins of cellular 
biochemistry. 
The function of the other components of lung surfactant 
are not so easily defined. Because DPPC does not have the 
properties of rapid adsorption and spreading, the function 
of the other components may relate to assisting adsorption 
and spreading, and investigations have been performed with 
this idea in mind. The literature presents conflicting 
evidence about the function of these components so that no 
definite statement can be made at this time. 
The negatively-charged lipids, eg PG, were found to 
increase adsorption of lipid to the surface and enhance 
formation of tubular myelin in studies by King & MacBeth 
(1981). In contrast, Beppu, Clements & Goerke (1983) and 
Obladen, Brendlein & Kempien (1979) did not find that the 
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negatively-charged lipids increased the adsorption of lipid 
to the surface. PG is known to be characteristic of mature 
lung surfactant. It increases during the late stages of 
gestation to replace phosphatidylinositol (PI) as the 
predominant negatively-charged phospholipid. The lavage 
fluid of adult respiratory distress patients contains an 
abnormally high ratio of PI/PG. Lung surfactant deficient 
states have abnormalities in the negatively-charged lipid 
component (Hallman, Spragg, Harrell, Moser & Gluck, 1982). 
Surfactant lipids other than DPPC generally have phase 
transition temperatures less than 37 degrees C and would be 
expected to enhance fluidization and spreadability at 37 
degrees C (Villalonga, 1968; Phillips & Hauser, 1974). 
would aid the formation of the monolayer. 
This 
Cholesterol may also contribute to surface film formation 
by enhancing bilayer instability (Keough, 1984). 
Surfactant apoproteins increase with gestational age in 
the amniotic fluid along with PG. Human lung apoproteins 
have been described as two bands on polyacrylamide gels 
under reducing conditions at 30,000-40,000 daltons and at 
60,000-70,000 daltons (Shelley, Balis, Paciga, Espinoza & 
Richman, 1982; Taeusch et al, 1983). Perhaps the larger 
protein is a dimer of the smaller apoprotein. These 
apoproteins are specific to the alveoli. They have been 
found to be associated with the lamellar bodies of the 
alveolar type II cells, but the mechanism of association is 
unknown. The apoprotein may be essential to the formation 
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of tubular myelin in the alveolar hypophase and aid 
adsorption of lipid to the surface film (Taeusch et al, 
1983; Benson, Williams, Sueishi, Goerke & Sargeant, 1984; 
King & MacBeth, 1981; Tanaka, Takei & Kanazawa, 1983; 
Notter, Finkelstein & Taubold, 1983). However, removal of 
90% of the proteins from an animal lung surfactant did not 
affect the surface properties of the resulting lipid when 
tested in a pulsating bubble surfactometer (Metcalfe, 
Enhorning & Possmayer, 1980; Yu, Harding, Smith & Possmayer, 
1983). 
Divalent cations, eg calcium, magnesium, may be needed by 
surfactant to achieve low surface tensions (King & Macbeth, 
1981; Benson et al 1984; Kobayashi & Robertson, 1983; Weber, 
Yu & Possmayer, 1983). Again, it is postulated that the 
divalent cation may aid the formation of tubular myelin. 
The formation of the surface monolayer of lipid involves 
some transformation of lipid present in bilayers present in 
the alveolar hypophase. Theoretical considerations of 
monolayer formation come from studies of spontaneous lipid 
conformations in an aqueous environment. Such studies have 
suggested that the lipid would exist as some form of lipid 
bilayer. Bilayer instability induced by calcium, PG, or 
apoprotein could lead to the presence of non-bilayer lipid 
conformations such as inverted micelles and inverted 
hexagonal phase from which a surface monolayer might form. 
Tubular myelin, the lipid aggregate structures in the 
hypophase, may contain lipid in bilayer and unstable · bilayer 
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forms from which the surface monolayer film is formed. 
Alternatively, the tubular myelin may be produced 
concomitantly with the lipid monolayer as another nonbilayer 
conformation (Keough, 1984). 
1.6 Respiratory distress syndrome of the newborn 
Respiratory distress syndrome of the newborn, or hyaline 
membrane disease is associated with surfactant deficiency. 
Extracts of lung minces from infants with this syndrome fail 
to reach low surface tensions (Avery & Mead, 1959). The 
surfactant deficiency is associated with immaturity of the 
lung and type II surfactant-producing cells. 
Increased incidence of infant respiratory distress 
syndrome is seen in premature newborns (Avery & Mead, 1959; 
Avery et al 1973; Usher, 
asphyxia (Rokos, Vaeusorn, 
Allen & McLean, 1971), perinatal 
Nachman & Avery, 1968), familial 
disposition (Graven & Misenheimer, 1965), male sex (Naeye, 
Burt, Wright, Blanc & Tatter, 1971), maternal diabetes 
mellitus (Hubbell & Drorbaugh, 1965), maternal obesity 
(Naeye, Freeman & Blanc, 1974), and hypothyroidism (Gibson, 
Blackmore, Wijeratne & Wrathall, 1976). These conditions 
may be speculated to retard development of the lung 
surfactant system during fetal maturation. Corticosteroids 
are used to stimulate maturation of the surfactant system in 
cases of premature labour (Avery et al, 1973; Liggins, 1969; 
Liggins & Howie, 1972). They accelerate epithelial 
maturation in the developing lung (Kikkawa, Kaibara, 
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Motoyama, Orzalesi & Cook, 1971; Motoyama, Orzalesi, 
Kikkawa, Cook, Zigas, Kaibara & Wu, 1971). A peptide factor 
from fibroblasts which are apposed to type II cells may be 
important in regulating the response of the alveolar 
epithelium to steroids (Smith, 1979; Marin, Dameron & 
Relier, 1982). Stress and the B-adrenergic agonists can 
stimulate secretion of DPPC from immature type II cells. 
The lung matures rapidly during the last quarter of 
gestation. 
production. 
DPPC production is markedly increased, as is PG 
The ratio of lecithin to sphingomyelin is used 
as a maturity index of fetal lung (Gluck, Kulovich, Borer, 
Brenner, Anderson & Spellacy, 1971). Ratios of 2:1 or 
greater reliably indicate maturity, whereas ratios of 
1.5-2:1 are less reliable (Harvey, Parkinson & Campbell, 
1975). Infants with RDS have both reduced quantities and 
qualitative changes in the lecithins of their lungs. The 
qualitative changes include i) a decreased proportion of 
disaturated phosphatidylcholine and ii) an increase in 
lipids which have acyl chains with increased fluidity at 37 
degrees C (Shelley, Kovacevic, Paciga & Balis, 1979; Morley, 
Hill, Brown, Barson & Davis, 1982; Keough, 1984). Both the 
reduction in DPPC and the increase in unsaturated fluid 
lipids would contribute to surfactant dysfunction. 
The increase of PG in amniotic fluid is also an index of 
fetal lung maturity (Kulovich, Hallman & Gluck, 1979). PG 
may function to increase DPPC production as it activates 
cholinephosphate cytidylyltransferase, an enzyme in the 
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synthetic pathway of DPPC (Stern, Kovac & Weinhold, 1978; 
Feldman, Kovac, Drunginis & Weinhold, 1978). 
Recently, a specific surfactant inhibitor has been 
described in the airways of premature lambs and infants with 
RDS (Ikegami, Jacobs & Jobe, 1983; Jobe, Ikegami, Jacobs, 
Jones & Conaway, 1983). 
leaking lung membranes. 
This inhibitor is associated with 
It is a protein but has been only 
partially characterized. 
Studies of exogenous surfactant for infant RDS show great 
promise. Synthetic surfactants, surfactants made from 
bovine lung lavage lipids alone, and enriched with DPPC, and 
surfactants from human amniotic fluid are being tested. 
Theoretical considerations of DPPC content and the functions 
of fluidizing lipids, calcium and proteins to perhaps aid 
adsorption and spreading are relevant. Recent trials of 
surfactant replacement have claimed improved ventilation and 
survival in neonates with RDS (Fujiwara, Chida, Watabe, 
Maeta, Morita & Abe; 1980; Hallman, Merritt, Schneider, 
Epstein, Mannino, Edwards & Gluck, 1983; Smyth, Metcalfe, 
Duffy, Possmayer, Bryan & Enhorning, 1983). 
1.7 Adult Respiratory Distress Syndrome 
The adult respiratory distress syndrome (ARDS) describes 
acute respiratory failure in the setting of shock, sepsis, 
trauma and other illnesses. ARDS with sepsis and multiorgan 
failure is the principal cause of death in patients 
surviving initial hemorrhage or head injury. It is 
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estimated to affect 150,000 persons per year in the United 
States, and has a 50% mortality despite modern intensive 
care techniques (Connors, McCaffree & Rogers, 1981). 
victims are young and previously healthy. 
Many 
The respiratory failure involves an acute lung injury, a 
noncardiogenic pulmonary edema with leaking lung membranes, 
surfactant deficiency, and pulmonary fibrosis. If not 
lethal, resolution takes weeks with only partial 
reversibility in structural derangements. Permanent 
reduction in vital capacity or air flow obstruction is seen 
in one-third of survivors, but subtle abnormalities in 
exercise tolerance and gas exchange may persist in all cases 
(Elliot, Morris & Cengiz, 1981). 
The acute lung injury is usually secondary to a systemic 
illness, commonly shock, sepsis and trauma. Some systemic 
inflammatory components, eg. complement, leukocyte products, 
platelet products or fibrin degradation products injure the 
pulmonary capillary endothelium (Rinaldo & Rogers, 1982). 
The alveolar capillary endothelium is also damaged and a 
permeability type of pulmonary edema ensues. Concurrent 
damage to the surfactant system results in alveolar collapse 
and increased pulmonary edema. Sepsis and oxygen toxicity 
augment lung damage and likely influence the fibrotic 
response (Fisher, 1980). 
In the intensive care unit, life-support technology has 
improved greatly. The Swan-Ganz pulmonary artery catheter 
allows some distinction between hydrostatic and permeability 
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edema, and provides for monitoring of cardiopulmonary 
physiologic indices. The use of positive end-expiratory 
pressure (PEEP) ventilation has been claimed to improve 
survival in ARDS (Ashbaugh, Petty, Bigelow & Harris, 1969). 
PEEP may prevent surfactant aggregation (Wyszogrodski, 
Kyei-Aboagyek, Taeusch & Avery, 1975) and reduce oxygen 
toxicity by lowering inspired oxygen requirements (Petty & 
Ashbaugh, 1971). Steroids may modify both the inflammatory 
injury and fibrotic response (Hammerschmidt, White, Craddock 
& Jacob, 1979; Skubitz, Craddock, Hammerschmidt & August, 
1981; Hesterberg & Last, 1981; Brigham, Bowers & McKeen, 
1981), but the role of steroids in the management of RDS is 
not yet defined. Clinical trials testing the efficacy of 
steroids have not been conclusive. Sibbald, Anderson, Reid, 
Holliday & Driedger (1981) suggested that high-dose steroids 
may reduce alveolar-capillary permeability in human septic 
ARDS if used early in the course of the illness. However, 
Thompson, Gurley, Lutz, Jackson, Kvols & Morris (1976) did 
not find that high-dose steroids affected outcome or 
physiologic responses in a double-blinded study of 60 
patients with septic shock. Extracorporeal membrane 
oxygenation did not improve the mortality in a multicentre 
study (NIH, 1979). 
Clinical management of ARDS has not been very successful 
in reducing the mortality of the disease. Treatment to date 
may be considered as aggressively supportive. Therapeutic 
considerations now necessarily will come from the study of 
pathogenic mechanisms. 
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The pathology of ARDS lungs shows capillary microthrombi, 
endothelial damage, an interstitium filled with mesenchymal 
and inflammatory cells, interstitial edema and hemorrhage, 
loss of alveolar epithelial type I cells and proliferation 
of type II cells. Destruction of normal lung architecture 
is followed by pulmonary vascular obliteration, lung 
parenchymal fibrosis and alveolar loss (Lamy, Fallat, 
Koeniger, Dietrich, Ratliff, Eberhart, Tucker & Hill, 1976; 
Katzenstein, Bloor & Leibow, 1976). 
Investigation of the acute lung injury suggests that 
complement activation could be a factor common to several 
etiologic illnesses, eg. sepsis, shock, trauma, 
pancreatitis, burns, endotoxemia, soft tissue injury, and 
cardiopulmonary bypass. Complement activation recruits 
neutrophils (Craddock, Hammerschmidt, White, Dalmasso & 
Jacob, 1977). Neutrophils can damage the pulmonary 
endothelium, interstitium and alveolar epithelium through 
lysosomal superoxide radicals (Sacks, Moldow, Craddock, 
Bowers & Jacob, 1978) and proteases (Janoff, White, Carp, 
Hare!, Dearing & Lee, 1979). Neutrophil proteases can cause 
intravascular coagulation and platelet aggregation. 
Platelet-fibrin thrombi have been observed in ARDS lungs 
(Saldeen, 1976). Fibrin degradation products and 
prostaglandins and leukotrienes have both neutrophil 
chemotactic and microvascular permeability altering 
properties (Manwaring, Thorning & Curreri, 1978; Piper, 
1983). Perhaps all of these systems - complement, 
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neutrophils, platelets, coagulation - are involved in the 
acute lung injury of ARDS. 
the effects of each other. 
They may potentiate and amplify 
It may not be that one system is 
solely responsible for the lung injury, although for 
therapeutic approaches this would be ideal. 
Normal defense mechanisms may be deficient in the states 
predisposing to ARDS. Fibronectin is a glycoprotein that 
exists in tissue as an intercellular adhesive and in the 
plasma as an opsonizing factor. Fibronectin depletion in 
sepsis has been observed (Saba & DiLuzio, 1969; Schumacker & 
Saba, 1980). This would both increase alveolar-capillary 
membrane permeability and decrease the effectiveness of the 
reticuloendothelial system to clear particulate microthrombi 
and bacterial toxins. Antiprotease defense against 
leucocyte proteases may be impaired. Alpha-1-antitrypsin is 
an antiprotease that is found to be inactivated in the lung 
lavage of ARDS patients (Carp & Janoff, 1980; Bruce, Boat, 
Martin, Dearborn & Fanaroff, 1981). 
For reviews of ARDS see Moore, Lyons, Pierce, Morgan, 
Drinker, MacArthur & Dammin (1969), Connors et al (1981), 
and Rinaldo & Rogers (1982). 
1.8 Respiratory distress following cardiopulmonary bypass 
Following cardiopulmonary bypass operations (CPB), 
variable degrees of lung dysfunction are seen. Most 
commonly today there are minor atelectasis and slight 
decreases in lung volume. Respiratory distress syndrome 
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(RDS), which was quite common before hemodilution techniques 
were instituted, occurs infrequently in the whole patient 
patient population, but RDS still remains a significant 
complication of CPB especially in cases of prolonged bypass 
and in children (Kirklin, Westaby, Blackstone, Kirklin, 
Chenoweth & Pacifico, 1983). 
The RDS which follows CPB operations exhibits clinical and 
pathophysiologic characteristics seen in other forms of 
ARDS. There is a permeability type of pulmonary edema, 
atelectasis, loss of lung volumes, increased shunting, 
impaired gas exchange, and the tendency to infection and 
multiple organ failure (Ratliff, Young, Hackel, Mikat & 
Wilson, 1973; Wilson, 1974). In such states, the mortality 
is high. Pathophysiologically, exposure of the blood to the 
extracorporeal circulation - the foreign surfaces of plastic 
(polyvinyl chloride) tubing, the stress and shear forces of 
roller pumps and the suction apparatus - causes damage to 
blood components. Microaggregates of damaged blood 
components and a complement-initiated inflammatory response 
are seen (Kirklin et al, 1983; Craddock, Fehr, Brigham, 
Kronenberg & Jacob, 1977). The lung vascular endothelium is 
damaged (Ionescu, 1981). The interstitium shows hemorrhage, 
edema and infiltrates of polymorphs. The alveolar 
epithelial cells are damaged. The pathogenic mechanisms of 
complement, leukocyte superoxide radicals and proteases, 
platelets, prostaglandins and leukotrienes, and fibrin 
degradation products may be invoked in this acute injury to 
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the lung. As well, some investigators have associated the 
onset of RDS following CPB with possible anaphylactic 
reactions to fresh frozen plasma (Hashim, Kay, Hammond, Kopf 
& Geha, 1984; O'Connor, Erskine & Pringle, 1981) and to 
heparin-protamine interaction (Best, Sinosich, Teisner, 
Grudzinskas & Fisher, 1984; Olinger, Becker & Bonchek, 
1980). 
Surfactant dysfunction has been investigated as part of 
the lung injury following CPB. Extracts of minces of lung 
specimens from patients who died following CPB showed 
increased surface tensions (18 mN/m for ARDS lungs vs 7 mN/m 
for normals) (Gardner, Finley & Tooley, 1962). Extracts of 
minces of lungs from dogs subjected to CPB also showed 
increased surface tensions (Gardner et al, 1962; Hepps, Roe, 
Wright & Gardner, 1963; Mandelbaum & Giammona, 1964; 
Panossian, Hagstrom, Nehlsen & Veith, 1969; Camishion, 
Fraimow, Kelsey, Tokunaga, Davies, Joshi, Cathcart & 
Pierucci, 1968). 
The surfactant dysfunction may result from decreased 
production of surfactant or production of dysfunctional 
surfactant, increased breakdown of surfactant components, or 
surfactant inactivation. Damage to the alveolar epithelial 
type II cells may cause decreased production of surfactant. 
The injury would seem more likely to result from the 
inflammatory response than from ischemia due to pulmonary 
artery occlusion during the CPB. In isolated dog lung 
perfusions, periarterial hemorrhage and edema preceded any 
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increase in minimum surface tensions of lung extracts 
(Panossian et al, 1969). Occlusion of the pulmonary artery 
in dogs produced surfactant dysfunction only after 16 hours 
of ligation (Gardner et al, 1962; Mandelbaum & Giammona, 
1964; Morgan & Edmunds, 1967). When one lung was kept 
ischemic by clamping of the pulmonary artery during CPB, it 
did not develop microscopic lung injury, but the lung whose 
pulmonary artery was left open did develop such changes 
(Lesage, Tsuchioka, Young & Sealy, 1966). 
Evidence for decreased production or increased turnover of 
surfactant is that a reduction in the lamellar bodies of 
alveolar type II cells was seen post-CPB in dogs (Baritussio 
& Clements, 1981; Sobonya, Kleinerman, Primiano & Chester, 
1972). Evidence for increased turnover of surfactant is 
that interruption of pulmonary blood flow during CPB may 
result in increased surfactant removal from the lung 
(Morgan, 1971). 
The effects of hemodilution have been tested by 
examination of extracts of minces of lungs from dogs on CPB 
(Camishion et al, 1968) With whole blood prime, increased 
minimum surface tensions were observed at the end of the CPB 
of one hour duration. However with hemodilution pump 
priming techniques, there was no increase in minimum surface 
tensions of the extracts until 14 hours after CPB. It was 
suggested that hemodilution protected by diluting a plasma 
inhibitor of surfactant activity produced during CPB. 
In another study, extracts of minces of lungs from dogs 
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placed on CPB were tested 24 hours after bypass (Hepps et 
1963). The extracts showed a mean minimum surface al, 
tension on the surface balance of 22 mN/m when whole blood 
prime was used in the pump, compared with 11 mN/m when 
hemodiluted blood was used. 
The timing of the lung injury in relation to the CPB and 
the timing of surfactant dysfunction may not be the same. 
With respect to the timing of surfactant dysfunction, 
decreased surface activity was seen immediately after 1-2 
hours of CPB with whole blood prime (Camishion et al, 1968), 
and after 15-24 hours with hemodilution techniques (Hepps et 
al, 1963). With respect to the timing of the lung injury 
and the timing of the leaking lung membranes, tracer studies 
with labelled albumin demonstrated maximum alveolar-
capillary leak at 2 hours following CPB (hemodilution 
technique) of 1-2 hours duration in patients (Royston, 
Gatley, Higenbottam, Wallwork & Minty, 1983). Maximum lung 
damage as indicated by decreased levels of serum angiotensin 
converting enzyme (SACE), a lung endothelial enzyme, also 
occured at 2 hours following CPB. Improvement of the leak 
and SAGE levels was seen by 48 hours after CPB. 
Our studies address the possibility that surfactant 
dysfunction may result from inhibitors which leak into the 
The alveoli from the plasma during the acute lung injury. 
timing of production of such postulated inhibitors may 
concur with timing of the lung injury immediately following 
CPB, or sometime later with the observed timing of 
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surfactant dysfunction (eg. at 15-24 hours with hemodilution 
techniques). 
1.9 Surfactant and ARDS 
The abnormalities of lung mechanics in ARDS~ namely 
atelectasis, decreased lung volumes and increased 
compliance, fit well with surfactant dysfunction. As well, 
surfactant deficiency would increase pulmonary edema, and 
decrease normal particulate and bacterial clearance 
mechanisms (Hallman et al, 1982; Notter & Morrow, 1975; 
Notter & Shapiro, 1981; Schwartz & Christman, 1979; 
Schlimmer et al, 1983). Surfactant abnormalities are likely 
part of the consequences of the primary lung injury rather 
than a mechanism of primary injury. 
Investigation of surfactant in ARDS has shown decreased 
function and abnormal compostion. Abnormal lipid-protein 
aggregates were observed in surfactant from patients with 
ARDS (Petty, Reiss~ Paul, Silvers & Elkins, 1977; Petty, 
Silvers, Paul & Stanford, 1979). The surfactant had minimum 
surface tensions on film compression comparable to that of 
normals (18 mN/m) but the surfactant from the ARDS lungs had 
a higher compressibility than normals, ie. compression 
produced hysteresis loops more like those of pure proteins, 
than of DPPC. In surfactant prepared from extracts of 
minces of lungs from patients who died with ARDS, the DPPC 
content was decreased relative to other lipids (von Wichert 
& Kohl, 1977). It was concluded that the ineffective 
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surface activity seen in ARDS surfactant was the result of 
decreased DPPC content. 
Bronchoalveolar lavage (BAL) from patients with ARDS, and 
other respiratory diseases, eg. pneumonia, malignancy, and 
chronic obstructive lung disease, was compared with that 
from normal volunteers (Hallman et al, 1982). The total 
phospholipid of ARDS BAL was not much different from that of 
normals or from other respiratory diseases, but the 
lecithin/sphingomyelin ratio, PG and disaturated lecithin 
were low in ARDS BAL. Moreover, these indices normalized 
with recovery of lung function. BAL preparations from ARDS 
patients were not surface active compared with BAL from 
normals (minimum surface tensions of 14-20 mN/m and 3-5 
mN/m, respectively). Phospholipase A activity was low in 
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BAL from ARDS patients compared with that from normals and 
the other lung diseases, suggesting no increase in the 
catabolism of phospholipids in ARDS. Plasma myoinositol in 
ARDS patients was low unlike newborns with RDS where high 
plasma myoinositol levels may decrease synthesis of PG. 
In another study, BAL from patients with ARDS was found to 
contain a reduced proportion of palmitic acid in the total 
fatty acid compared with that from a control group of 
patients undergoing bronchoscopy for local lung lesions 
(Baughman, Stein, MacGee, Rashkin & Sahebjami, 1984). 
Animal models of acute lung injury also show surfactant 
abnormalities. Pulmonary edema has been induced in dogs 
with rapid intravenous dextran infusion (Said, Avery, Davis, 
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Banerjee & El-Gohary, 1965). The surface activity of 
extracts from damaged lung were reduced when compared with 
that from normal lung. This surfactant dysfunction was 
associated with abnormal pressure-volume curves and 
morphologic and histologic damage. Oleic acid has been 
injected intravenously into cats (Hamilton, Hustead, 
Peltier, Kuenzig, Strandmark & Rosenbaum, 1964). Extracts 
of lung minces from treated animals showed increased minimum 
surface tension (22 mN/m) when compared with that of control 
lungs ((10 mN/m). The lungs were grossly hemorrhagic, the 
alveoli filled with blood and exudate, and there was 
disorganization of the alveolar architecture. In dogs 
exposed to high oxygen tensions respiratory distress and 
pulmonary edema was seen (Morgan, Finley, Huber & Failkow, 
1965). The BAL of dogs with pulmonary edema showed high 
surface tensions and a decrease in the proportion of 
palmitic acid and disaturated lecithin in the total lipids 
of the BAL when compared with BAL from normals. Electron 
microscopy showed alterations in the structure of the 
lamellar bodies of the type II alveolar epithelial cells. 
Another investigation of high oxygen tensions in dogs showed 
decreased surface activity of lung lavage fluid obtained 
after 5 hours of exposure (Trapp, Patrick & Oforsagd, 1971). 
The total quantity of phospholipid and palmitate was 
decreased in the BAL of treated dogs in comparison to that 
from control dogs. N-nitroso-N-methylurethane has been 
injected subcutaneously into dogs (Ryan, Liau, Bell, Hashim 
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& Barrett, 1981). The lungs showed microatelectasis, 
interstitial and alveolar edema, and hyaline membranes. BAL 
and lung tissue were analysed for disaturated 
phosphatidylcholine (PC). Both alveolar and type II cell 
disaturated PC levels were decreased compared to a control 
group, suggesting that 
injury to the alveolar 
surfactant changes resulted from 
type II cells. Lung injury has been 
induced in mice with butylated hydroxytoluene (Smith, 1983). 
Lamellar body volume density was decreased at the time of 
alveolar type II cell mitosis. This implied that the 
metabolism of proliferating type II alveolar cells at the 
time of injury was not directed to surfactant production. 
Surfactant dysfunction may result from decreased 
production, increased breakdown, or inactivation. In acute 
lung injury there is evidence for decreased production of 
DPPC. Not much investigation has addressed the breakdown 
and turnover of surfactant in acute lung injury. The 
possibility of surfactant inactivation by plasma inhibitors 
reaching the alveoli through damaged lung blood-air 
membranes has been investigated and will be reviewed in the 
next section. 
1.10 Surfactant inhibitors including their association with 
cardiopulmonary bypass 
Gardner et al (1962) tested extracts of minces from normal 
dog lungs on a surface tension balance. The compression 
cycle was timed at 30 minutes. Heparinized whole blood was 
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pumped through a bubble oxygenator in vitro for several 
hours, then 5 ml of this blood was mixed with the extract of 
normal dog lung. The minimum surface tensions were 18-22 
mN/m on compression (n=6). When the same extracts were 
mixed with unperfused blood, the minimum surface tensions 
were 6-8 mN/m. It was concluded that blood exposed to CPB 
contained surfactant inhibitors whereas normal blood did not 
prevent surfactant from reaching low surface tensions on the 
surface balance. These inhibitors were suggested to be free 
lipids released following the denaturation of protein. 
Protein is known to be denatured by CPB. 
Mandelbaum & Giammona (1964) added dog blood to extracts 
of minces from normal dog lungs. Normal blood, blood aged 
for 2-4 hours at room temperature, and blood pumped through 
an oxygenator circuit with no tissue contact for 2-4 hours 
increased the minimum surface tension from 10 mN/m to 28-32 
mN/m. However blood taken from dogs during 5 hours of CPB 
did not increase the minimum surface tension significantly. 
The quantity of blood added was unstated. It was concluded 
that a circulating surfactant inhibitor had been removed 
from the blood during CPB in the dogs. Neither Gardner or 
Mandelbaum described how the blood and lung extracts were 
mixed or in what quantities they were mixed prior to testing 
on the surface balance. 
Tierney & Johnson (1965) tested extracts of minces of 
rabbit lungs on the surface balance. Three grams of lung 
were minced, then stirred for 5 minutes in 50 ml of · 0.9% 
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saline. The extracts were poured into the surface balance 
trough through cotton gauze to 
to 6 ml of normal rabbit blood 
remove tissue pieces. 
or serum was added to 
If 
the 
saline during extraction, the minimum surface tension was 
usually but not always elevated. The minimum surface 
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tension was also increased if i) the temperature was raised 
to 42 degrees C, ii) the extract was prepared with distilled 
water, iii) phospholipase C was incubated with the extract 
and iv) cholesterol or oleic acid was added to the surface. 
If 10 ml of blood was added beneath the surface film, no 
significant effect upon the minimum surface tension was 
seen. The method of adding the blood beneath the surface 
was not stated. They concluded that adequate mixing of 
blood and a sufficient quantity of blood were essential 
before significant change in minimum surface tension would 
occur. They concurred with Gardner et al (1962) that free 
lipid could inhibit surfactant. Alterations in the 
pressure-volume characteristics of the lung could result 
when the blood-air barrier was damaged and the composition 
of the surface changed. 
Taylor & Abrams (1966) extracted surfactant from rabbit, 
lamb and human lungs. Extracts were mixed with human plasma 
protein fractions, incubated for 5 minutes then tested on a 
subphase of saline on the surface balance. Plasminogen, 
plasmin, albumin, and gamma-globulins when mixed in 
equimolar or greater amounts with surfactant did not affect 
the minimum surface tension of the surfactant. The 
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molecular weight of the surfactant was not specified. 
However an equimolar amount of fibrinogen did increase the 
minimum surface tension, and the minimum surface tension was 
increased with increasing amounts of fibrinogen. The 
protein-surfactant mixture was placed on the surface using 
the glass rod method of Trurnit (1960). 
Balis, Shelley, McCue & Rappaport (1971) mixed washings 
from rabbit lungs with serum and citrated plasma in a ratio 
of 5:1. The minimum surface tension of the mixtures placed 
on a subphase of Ringer's solution was elevated to 18-20 
mN/m. Centrifugation of the mixtures produced a pellet 
which had high surface activity (minimum surface tensions of 
0-5 mN/m). This was a reversible form of surfactant 
inactivation. When lung washing was mixed with heparinized 
or recalcified citrated plasma, a clot developed in the 
mixture. The clot contained myeloid figures in the 
fibrinous deposits. Eluate of the washing-plasma mixture 
yielded a pellet after centrifugation which had high minimum 
surface tensions (20-25 mN/m). It was suggested that this 
type of surfactant inactivation depleted surfactant by 
coagulation and might represent a mechanism of surfactant 
inactivation in hyaline membrane disease. 
Miyahara (1969) tested mixtures of fibrinogen, fibrin and 
fibrinogen breakdown products, serum, plasma, and whole 
blood with lung washings, and found that all had inhibitory 
effects on the surface activity of the surfactant. 
Tabak & Notter (1977) added proteins to a preformed 
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surface monolayer of DPPC using the glass rod method of 
Trurnit (1960). Bovine fibrinogen and albumin did not 
affect the minimum surface tension in ratios of 1-2 
molecules of protein per molecule of phospholipid at the 
surface. 
Rufer & Stolz (1969) found that on the surface balance, 
pure protein hypophases (albumin, globulin, fibrinogen) were 
surface active. Monolayers of rat lung surfactant and pure 
DPPC placed on the protein hypophases showed increased 
minimum surface tensions and decreased hysteresis. The rat 
lung surfactant was added to the surface of the hypophase as 
a dry powder. The DPPC was added to the surface using a 50% 
propandiol solution as the spreading agent. 
In summary, the literature presented a confusing picture 
of the effects of blood or blood components on lung 
surfactant activity (Table 1-1). Surfactant inhibition was 
tested as the ability to prevent low surface tension on 
compression using the Langmuir-Wilhelmy surface balance. 
Possible explanations for the variability in the results are 
the varied methods of i) preparing the lung surfactant, ii) 
mixing the surfactant and the blood or blood component, and 
iii) testing the mixture on the surface balance. 
1.11 Statement of the problem 
The literature relevant to the hypothesis of surfactant 
dysfunction due to inactivation by plasma inhibitors has 
been reviewed. It was proposed to seek answers to the 
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Table 1-1: Literature findings on surfactant inhibition 
Does normal blood inhibit surfactant? 
no 
Gardner et al (1962) 
Tierney et al (1965) 
(blood beneath the 
surface) 
yes 
Mandelbaum et al (1964) 
Tierney et al (1965) 
(usually, when blood 
mixed with lung extract) 
Do plasma proteins inhibit surfactant? 
no 
Taylor et 
(albumin, 
al (1966) 
globulins) 
Tabak et al (1977) 
yes 
Taylor et al (1966) 
(fibrinogen only) 
Balis et al (1971) 
Miyahara (1969) 
Rufer et al (1969) 
Does CPB blood inhibit surfactant? 
no 
Mandelbaum et al 
(1964) (in vivo) 
yes 
Mandelbaum et al (1964) 
(in vitro) 
Gardner et al (1962) 
(in vitro) 
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following questions as the answers were not clear from the 
literature: 
1. Do normal plasma and serum inhibit surfactant? 
z. Does CPB produce or increase surfactant inhibitors 
in plasma, and if so, what time are these 
inhibitors produced in relation to the CPB? 
3. Is CPB in children different from in adults with 
respect to the production of possible surfactant 
inhibitors? 
4. What is the nature of any observed inhibition? 
Information gained from this study should allow a clearer 
understanding of lung dysfunction involving leaking 
membranes with entrance of plasma or plasma fractions into 
the alveolar spaces. 
1.12 Research plan 
This study of surfactant inhibition involved tests of the 
ability of lung surfactant to reach low surface tensions on 
a surface tension balance. Inhibition was defined as the 
prevention of the surfactant from reaching low surface 
tension. As previously stated, there are differences in the 
methods used to test surfactant-potential inhibitor 
mixtures. A precise definition of methods of testing was 
required. 
The preparations for testing surfactant-potential 
inhibitor mixtures involved the preparation of lung 
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surfactant and definition of the test conditions. The test 
conditions considered were the surface balance conditions 
(treatment of the trough, the hypophase solution, the 
layering of the test sample on the hypophase solution, the 
time of equilibration on the surface before testing, the 
solution used for spreading the test material), the method 
of plasma preparation, the method of mixing the surfactant 
and potential inhibitor, and the time of interaction of the 
mixture before testing. 
Tests of normals and patients undergoing CPB surgery were 
examined to investigate the possible presence of inhibitors 
in the blood of normal adults and in adult and child 
patients. 
The nature of the inhibition was investigated by comparing 
the effects of plasma, serum and various plasma protein 
fractions on surfactant. As well, an attempt was made to 
define the chemical nature of the inhibitor. Also, an 
effort was made to determine if the specific surfactant 
inhibitor of premature infants and lambs with RDS (Ikegami 
et al, 1983; Jobe et al, 1983) was present in the plasma 
from normal individuals and CPB patients. 
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Chapter 2 
Preparations 
2.1 Preparation of Lung Surfactant 
Surfactant used for most of the tests was prepared from 
pig lungs. Temporal and fiscal reasons of economy were: 
freshly removed lungs from pigs (killed by electrocution) 
were readily obtained from Newfoundland Farm Products~ and 
the yield of surfactant per man-hour of preparation was 
higher using pig lungs than with smaller, more expensive 
laboratory animals. One batch of surfactant from rabbits 
was also used. 
Surfactant can be prepared from extracts of lung minces or 
from lung lavage. Lung lavage yields a "cleaner'' surfactant 
which is less contaminated by cellular constituents (Morgan 
et al, 1965b; Tanaka & Takei, 1983). Lung lavage was used 
for the preparations in this study. 
Pig lungs were obtained from the local abbatoir and 
transported to the laboratory on ice. The trachea was 
intubated with a plastic Tygon tube and tied in place with 
household string. Whole lung lavage was performed with a 
cold saline solution, solution #1, containing NaCl .15M, 
MgCl .003M, CaCl .003M, and TRAM .OOSM, adjusted t~ pH 7.4 
2 2 
(see appendix A.l) (King & Clements, 1972). The lungs were 
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filled with the saline (approximately 2 litres) then drained 
by turning them upside-down and gently compressing them 
manually. This was repeated three times. The recovery 
volumes were not recorded as it was not intended to 
quanitate the yield of the surfactant. The lungs were 
received with some sections collapsed and hemorrhaged. 
Foamy, blood-tinged fluid was seen in the cut tracheae. 
This may have been partly the result of rough handling at 
the abbatoir, and partly may have been associated with the 
pigs' reaction to slaughter. 
The initial procedure for purificat i on of surfactant was a 
modification of the technique described by Yu, Harding, 
Smith & Possmayer (1983) for cow lungs (see appendix A.2). 
This involved 3 centrifugation steps using a saline 
solution. With dialysis and lyophilization the total time 
of processing the preparation was 4 days. The resuspended 
pig lung surfactant had good surface active properties when 
tested on the surface balance (minimum surface tension < 10 
mN/m), but contained a relatively low phospholipid content 
as determined by phosphorus assay (appendix A.6) and as 
compared to that reported in the literature, which is 80-90% 
by weight (Table 2-1). 
The low phospholipid content was thought to reflect 
contaminating materials, mainly prote i ns. Since 
contaminating proteins and other blood constituents could be 
confounding to subsequent tests of mixtures of surfactant 
and plasma, other processing techniques were used to ·improve 
the phospholipid content. 
date of colour 
harvest lavage 
13/7 bloody 
bloody 
18/7 bloody 
bloody 
clean 
1/8 bloody 
bloody 
8/8 bloody 
bloody 
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Table 2-1: 
Pigsam preparations: 
object to produce surfactant 
with low surface tension (gamma-min) 
of less than 10 mN/m and containing 
80-90% phospholipid (PL) by weight 
of processing gamma-min 
technique on surface 
(10 ug load) 
Yu et al (1983) 5 & 7 
Yu et al (1983) 0 & 0 
and NaBr 
King & 2 & 3 
Clements (1972) 
Yu et al (1983) 5' 7 & 0 
and NaBr 
Yu et al (1983) 2,0 & 0 
Yu et al (1983) 0,5 & 0 
and NaBr 
Yu et al (1983) 4 & 5 
Na Br and 
Shelley et al 
(1977) 
Yu et al (1983) 2 & 5 
and NaBr 
Yu et al (1983), 5 & 5 
Na Br and 
Shelley et al 
(1977) 
% PL 
by wt 
SO% 
86% 
85% 
85% 
74% 
85% 
83% 
68% 
86% 
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The procedure of King & Clements (1972) and the procedure 
of Shelley, Paciga & Balis (1977) were tried. These 
techniques involved separating surfactant with a high 
phospholipid content from contaminating proteins. NaBr was 
used to create density gradients, and centrifugation 
separated the surfactant from the proteins as they settled 
at their isopycnic densities in the gradient. It was noted 
that the NaBr floatation step removed the blood-staining of 
the material and the material became white. 
The King & Clements (1972) protocol was followed for the 
production of their "W1" fraction containing the surface 
active material. The modification of the protocol of 
Shelley et al (1977) used in this study, involved using 
material prepared from the protocol of Yu et al (1983) and 
which had been centrifuged in one NaBr floatation step, then 
centrifuging this material once in a discontinuous NaBr 
density gradient. The method of this study differed from 
that of Shelley et al (1977) only in that two similar 
discontinuous NaBr density gradient centrifugations were 
used in their protocol. 
It was found that once the phospholipid content was about 
85% by weight, additional centrifugations did not increase 
the phospholipid content higher than 85%. For the test 
preparation used in the study (date of harvest 1/8, Table 
2-1), one density gradient centrifugation improved the 
phospholipid content to 85% by weight. 
The protocol from which our stock supply of surfactant was 
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produced included one centrifugation to remove cells, a 
centrifugation to pellet the surfactant, one centrifugation 
with NaBr to float the surfactant, a second pelleting 
centrifugation, dialysis and lyophilization (appendix A.2). 
The phospholipid fraction was 85% by weight as determined by 
phosphorus assay (lipid weight taken as 25 times the 
phosphorus weight), and had gamma-min less than 10 mN/m. 
Gamma-min is the surface tension obtained on compression of 
a surfactant monolayer at minimum surface area of the 
surface tension balance. The methods of testing surface 
tension on the surface tension balance are described in the 
following section 2.2. In Table 2-1, this surfactant is 
listed as pigsam harvested on 1/8, processed through Yu et 
al (1977) and NaBr. Seven pig lungs were used, yielding 
about 200 mg of lyophilized material. For testing, the 
lyophilized material was resuspended in solution #1 using a 
glass stirring rod, vortexing and sonication (appendix A.6). 
The criteria for satisfactory surfactant used in this 
study, employed % phospholipid (PL) by weight and gamma-min 
< 10 mN/m. Other characteristics for surfactant have been 
stated in the literature (Notter & Shapiro, 1981; Taeusch et 
al, 1983) but were not tested at this time. 
Once the processed material was 85% PL by weight further 
centrifugations did not increase the % PL composition. This 
may indicate association of the specific lung apoprotein to 
the PL in the surfactant. It is interesting to note that 
the surfactant preparations with low % PL composition; which 
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. 11·ed a high protein content, also had low minimum surface 1IDP 
tensions (Table 2-1). 
2 .2 Test conditions for the surface balance 
surface tension measurements were performed on a 
Kimray-Greenfield surfactometer (a Langmuir-Wilhelmy 
balance, Figure 2-1) housed in a box to maintain temperature 
and humidity. The air temperature was 37 + 2 degrees C and 
the subphase temperature was 33 + 2 degrees C. An open 
beaker of H 0 was kept within the box. 
2 
The trough had an 
available surface area of 53.4 em 
2 
2 
which could be compressed 
to 7.5 em • A cycle speed of compression and relaxation 
took 34 seconds. 
The balance was zeroed after the platinum flag had been 
roughened with fine emory paper, rinsed and heated to an 
orange colour over a bunsen burner. A subphase of 25 ml of 
solution #1, which was prepared with doubly distilled water 
(the second distillation using KMnO ), was poured into the 
4 
trough, and the surface cleaned by repetitive compression 
and aspiration until the surface tension was 70 mN/m. 
The sample to be tested was gently laid onto the surface 
of the subphase by touching a droplet formed at the end of a 
Hamilton syringe needle to the surface (Figure 2-2). 
An example of the surface tension hysteresis loop of a 
surfactant monolayer (Figure 2-3) compressed and expanded on 
the surface balance is found in Figure 2-4. Surfactant 
function was measured as the surface tension at the minimum 
surface area during the first compression. 
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Figure 2-1: A Langmuir-Wilhelmy surface tension balance 
Figure 2-2 Droplet technique for monolayer formation 
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moving dam dipping plate 
~igure 2- 3 Surfactant monolayer 
LaCl -DSPC-DPPC treatment 
3 
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The teflon trough and moving barrier were treated with 
solution of a saturated lecithin and lanthanum chloride 
(Hildebran et al, 1979; Goerke & Gonzales, 1981). Before 
treatment the teflon trough was rinsed with distilled water 
then methanol:chloroform, 1:1 v:v, and air-dried. The side 
walls of the trough and barrier dam were swabbed with a 
cotton-tipped applicator dipped in a solution of O.lM LaCl 
3 
and O.l25mM DSPC in methanol. This was allowed to dry for 
at least 5 minutes. 25 ml of solution #1 was placed in the 
trough. 5 ul of a 2 mg/ml DPPC solution in hexane:ethanol, 
9:1 v:v, was placed on the surface of the hypophase. The 
surface was then compressed for 3 cycles. A second 5 ul of 
the DPPC solution was placed on the surface and compressed 
for 3 cycles. 
The LaCl -DSPC-DPPC treatment of the trough seemed to 
3 
decrease the amount of leak of surface active material 
around the barrier dam and up the side walls of the trough. 
The compression shoulder approaching 5 mN/m was sharper and 
occured earlier during the compression phase for the treated 
troughs as compared with the untreated troughs (Figure 2-5). 
Test for surface leak 
An objective test of leak of surface active molecules from 
the surface and the performance of the balance was a test of 
area/molecule for DPPC. DPPC, 3 ul of a 2 mg/ml solution, 
was compressed on the surface. The area at which 20 mN/m 
surface 
tension 
mN/m 
·Figure 2-4 
0 
70 
% pool area 
14 100 
Example of surfactant hysteresis loop 
of surface tension 
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untreated 
LaC1 3 -DSPC-DPPC 
Figure 2-5 The effect of LaC1 3 -DSPC-DPPC 
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was reached was used to calculate the area/molecule ratio. 
This value was checked against the value of 45 
2 
angstroms /molecule for DPPC at 20 mN/m (Trauble, Eibl & 
Sawada, 1974). 
2 
Calculated values less than 45 
angstroms /molecule indicated that surface active molecules 
were being lost from the surface and that corrective 
measures were needed (eg. change of trough and/or barrier, 
or retreatment with LaCl -DSPC-DPPC). 
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Effect of the hypophase solution 
The effect of the hypophase solution was tested using a 
surface load of 10 ug of surfactant. The solutions tested 
were 
MgCl 
2 
solution #1 (with 0.15M NaCl, 0.003M CaCl , 
2 
0.003M 
0.005M TRAM, pH 7.4) and a 0.6M sucrose solution 
(with CaCl 0.003M, TRAM 0.005M, pH 7.4) (Baritussio, 
2 
Magoon, Goerke & Clements, 1981). Compression was started 5 
minutes after the surfactant had been placed on the surface. 
The minimum surface tensions (gamma-min) were: 
solution #1 2 & 5 mN/m 
sucrose - 2 & 3 mN/m. 
Effect of layering time 
The effect of the length of time from placing the 
surfactant on the surface to beginning compression (layering 
time) was tested using 10 ug of surfactant on a hypophase of 
solution #1. 
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The minimum surface tensions were: 
1 min 
3 min 
5 min 
4 & 4 mN/m 
3 & 4 mN/m 
2,5,0 & 7 mN/m 
10 min - 3 & 3 mN/m 
Effect of surfactant surface load 
The surface load of surfactant was tested using a 
hypophase of solution #1 and a layering time of 5 minutes. 
The minimum surface tensions were: 
10 ug 
20 ug 
2 & 5 mN/m 
3 & 4 mN/m 
Effect of spreading solution 
The spreading solution, which is the solution used to 
resuspend lyophilized surfactant, was tested with 10 ug of 
surfactant on a hypophase of solution #1. Recall that DPPC 
has poor spontaneous spreading characteristics. Two 
solutions were tested: solution #1 and an 
isopropanol:water, 2:1 v:v, solution. The effect of 
layering time was also considered since time for the 
isopropanol to evaporate and residual isopropanol on the 
surface might affect the ability of the surfactant to reach 
low surface tensions. 
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The minimum surface tensions were: 
isopropanol:water 6 & 6 mN/m (5 min layering) 
4 & 6 mN/m (10 min layering) 
solution #1 2 & 5 mN/m (5 min layering) 
3 & 3 mN/m (10 min layering) 
Summary 
There was no obvious difference between the hypophase 
solutions of sucrose and solution #1. There was no obvious 
difference between the layering times from 1 to 10 minutes. 
There was no obvious difference between the surfactant 
surface loads of 10 and 20 ug. There may be a difference in 
the spreading agents solution #1 and isopropanol:water. The 
isopropanol:water did not improve the gamma-min, and may 
have even moved it away from zero. The isopropanol may 
denature the protein of surfactant and plasma in subsequent 
testing and influence the results. 
2.3 Test conditions for surfactant-plasma interactions and 
methods of plasma preparation 
The effects of plasma on surfactant function have been 
tested with various methods on the surface balance. The 
method used in this study involved placing a premixed 
suspension of plasma and surfactant on the surface of a 
hypophase solution of saline. This model of surfactant and 
protein interaction tested the situation where surfactant 
and protein both exist at the alveolar air-water interface. 
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The initial collection of plasma from human subjects was 
performed with Vacutainer tubes containing heparin. Heparin 
was used as an anticoagulant instead of EDTA for two reasons: 
i) EDTA would chelate calcium which may be important for 
surfactant function, and ii) heparin is used as the anti-
coagulant during CPB. The blood was centrifuged in a bench-top 
centrifuge (IEC clinical centrifuge; setting = 6) for 5 
minutes and the plasma removed with a pasteur pipette. The 
total protein concentration of the plasma was determined 
using the Biuret method (Gornall, Bardawill & David, 1949) 
(appendix A.8). 
The teflon trough and barrier dam had been prepared with 
LaCl -DSPC-DPPC. 
3 
The hypophase solution used was solution 
#1, and the layering time 4 minutes. 
Surfactant and plasma were mixed in a glass vial by 
vortexing and by passing the mixture into and out of a SO ul 
Hamilton syringe seven times. The mixtures tested were 
surfactant-plasma at 2:1, 1:1, 1:2 v:v. The surfactant-
plasma mixture was placed on the surface with a constant 
surface load of 10 ug (5 ul of a 2 mg/ml solution) of 
surfactant. The time of interaction, ie. the time for 
mixing in the glass vial before placing on the surface of 
the hypophase, was tested at 5 and 30 minutes. The effect 
of dilution was tested by mixing the surfactant with a 
saline solution (Ringer's lactate) at 2:1, 1:1, 1:2 v:v. 
Again the surface load of surfactant was kept constant at 10 
ug. 
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The data showed that surfactant alone reached lower 
surface 
defined 
tensions than 
as surfactant 
mixtures of 
inhibition. 
surfactant and 
Figure 2-6 is 
plasma, 
an example 
of the surface tension diagrams of a mixture of surfactant 
(7.5 ug phospholipid) and plasma (10 ul or approximately 0.8 
mg total protein) and of surfactant (7.5 ug PL) alone. It 
was seen that the degree of surfactant inhibition increased 
with the amount of plasma added. Delta gamma-min, the 
difference in minimum surface tension of the surfactant-
plasma mixture from that of surfactant alone, was plotted on 
the y-axis vs the volume of plasma added on the x-axis 
(Figure 2-7). The gamma-min for each aliquot of resuspended 
pigsam had been tested before and after each series of tests 
of the mixtures of plasma and surfactant. It was determined 
that the line of best fit was linear for both the 5 min and 
30 min times of interaction, ie. delta gamma-min, a measure 
of the degree of inhibition, varied directly with the volume 
of plasma. There was no significant difference between the 
data for the 5 vs 30 minutes of interaction time, p).25. 
The statistical methods are discussed in section 2.4. 
There was no effect of dilution of surfactant with the 
saline solution on the gamma-min at 2:1, 1:1, 1:2 v:v, which 
corresponds to 2.5, 5.0, 7.5 ul of diluting solution, 
respectively. Further consideration of dilutional effects 
is considered in a later section. 
A question of the effect on plasma proteins by vacutainer 
rubber was raised. The literature suggested that the serum 
% pool area 
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levels of certain drugs may be lowered because the rubber 
maY displace the drug from alpha-1-glycoprotein binding 
sites (Ooi, Pozanski & Smith, 1980). In any event we chose 
to collect the blood subsequently using plain glass syringes 
and plain glass tubes with parafilm for covering. 
z.4 Statistical methods 
These methods were developed with the expert advice of 
Dr.A.Cornish, Department of Statistics, MUN. 
The data was plotted with (x,y) coordinates. The method 
for determining the line of best fit for the data used 
quadratic regression analysis. By definition of delta 
gamma-min, the line of best fit should go through the 
origin. 
If the line of best fit was linear and went through the 
origin, then for the regression line y=a+bx, the t-value, 
ie. the value of the t-statistic given by the regression, 
for the a term would not be significant. If a was 
significant, then the linear regression line of best fit for 
the data did not go through the origin. Within the range of 
x tested the linear regression line of best fit with the 
significant y-intercept (''a"), would better describe the 
data than a regression line forced through the origin. 
Between the origin and the lowest x value tested, the line 
may have a different slope. 
If the line of best fit was non-linear, then the quadratic 
term in the regression would have a significant t-vaiue. 
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Other lines of best fit may then be tested (eg. power, 
exponential, log) as these may be written as a polynomial to 
the n-th degree. If the quadratic term was not significant, 
then the linear regression line was truly the line of best 
fit· one need not apply other lines (eg. power, 
e~ponential, log) to the data. 
As determined, all groups were best described by linear 
regression, except one, the adult CPB-2, sam F group (a 
result of the next section on the study of the effect of CPB 
on surfactant inhibition). Comparisons between the groups 
were tested using the overall F-test method for coincident 
linear regressions (Zar, 1974). The lines of best fit were 
used for comparisons, not the forced lines through the 
origin. 
2.5 Rabbit surfactant control 
To check that the inhibitory effects of human plasma were 
not peculiar to pig lung surfactant, a small quantity of 
rabbit lung surfactant was prepared using the same protocol 
used for the BAL for pig lungs. The rabbit surfactant had a 
phospholipid content of 80% by weight as determined by 
phosphorus assay. 
Mixtures of normal adult human plasma and rabbit lung 
surfactant were tested under the same test conditions on the 
surface balance. It was observed that the plasma prevented 
the rabbit surfactant from reaching low surface tensions, 
and that the amount of inhibition varied directly with the 
surface load of plasma (Figure 2-8). 
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2 .6 Summary 
Plasma was shown to prevent surfactant from reaching low 
surface tensions under the stated conditions of testing. 
The result was not peculiar to pig lung surfactant. Methods 
of statistical comparisons between test groups were 
developed using regression analysis and an overall F-test. 
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Chapter 3 
A study of the effect of cardiopulmonary bypass on 
surfactant inhibitors 
3.1 Introduction 
It was observed in the last section that plasma inhibited 
surfactant. In this chapter the effect of CPB on plasma was 
investigated with regard to the production or elevation of 
levels of circulating surfactant inhibitors in the plasma. 
There is lung dysfunction following CPB which ranges in 
severity from minor atelectasis to RDS. RDS is a rare 
complication of elective adult cardiac surgery employing 
CPB, but is still seen with significant frequency in 
children and in cases with prolonged bypass. The CPB is 
thought to invoke an inflammatory response in the blood 
which injures the lung blood-air membranes. The hypothesis 
was that plasma components which leaked into the alveoli 
through the damaged membranes could inhibit surfactant from 
proper function. Studies on the effect of CPB on potential 
inhibitors in plasma had not been previously investigated in 
humans. 
The test groups consisted of normal adults, adult patients 
undergoing elective CPB surgery and child patients 
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undergoing CPB surgery. Protocols were approved by the 
Human Investigation Committee of the Faculty of Medicine, 
Memorial University of Newfoundland. Permission to collect 
blood was obtained from the hospitals, physicians and 
subjects involved. 
Samples were taken at several times perioperatively in the 
adult patients to examine the timing of surfactant 
dysfunction in relation to the timing of the lung injury. 
Hemodilution was used in all cases. Bubble oxygenators 
(Cobe) were used for most of the CPB but membrane 
oxygenators (Cobe) were also used occasionally. 
3.2 Methods 
The blood was collected using plain glass syringes and 
plain glass tubes with parafilm covering. Heparin was added 
to the tubes when plasma was required, at a dose of 30 
units/ml blood. 
Blood from the adult patients was collected at four times, 
all from an indwelling arterial line. The first sample, 
CPB-1, was taken on the morning of the operation before the 
patient was taken into the operating room. The second 
sample, CPB-2, was taken once the patient was asleep but 
before CPB was started, to account for possible effects of 
the anesthetic drugs. The third sample, CPB-3, was taken 
from the CPB circuit immediately on completion of CPB. The 
fourth sample, CPB-4, was taken 20-24 hours post-operatively 
in the intensive care unit. 
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Blood from the child patients was taken from an indwelling 
arterial line while the patient was asleep and before CPB 
was started. A second sample was taken immediately on 
completion of CPB. (see page 62a) 
The blood from the adult normals and the adult CPB groups, 
CPB-1 and CPB-2, was also used to prepare serum. 
Plasma prepared from the blood was kept at room temperature 
until testing. The tests of surfactant inhibition were done 
within ten hours of blood collection. The plasma-surfactant 
mixtures were mixed in a glass vial by vortexing and by passing 
the mixture into and out of a 50 ul Hamilton glass syringe. 
The mixture was allowed to interact for at least 5 minutes 
before testing. A hypophase of solution #1 was used in the 
teflon trough prepared with LaCl -DSPC-DPPC. 
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The mixture 
was added to the surface with the droplet technique and 
allowed to spread and equilibrate for 4 minutes before 
compression of the surface was started. The minimum surface 
tension, gamma-min, was the surface tension at minimum 
surface area on the first compression cycle. The total 
protein concentration of the plasma was determined by the 
Biuret method. The amount of plasma was varied while the 
surface load of surfactant was constant at 10 ug. The 
ability of the pigsam to reach low surface tension was 
checked by testing for the gamma-min of each aliquot of 
pigsam before and after each of the series of tests of the 
mixtures of plasma and surfactant. 
The effect of hemodilution on the possible inhibitory 
components was considered. From the literature it seemed 
62a 
In the pediatric patients, blood was taken once before 
CPB and once following CPB. Additional samples as in the 
adults, were not taken for reasons of patient comfort and the 
small blood volume in these pediatric patients. Also, the 
adult data on preliminary examination had not showed a 
significant effect between groups. 
The adults ranged in ages from 49 to 70, and the male to 
female ratio was 4:1. All of the adult patients underwent 
elective operations for coronary artery bypass grafting. 
The child patients ranged in ages from 6 months to 6 years. 
The male to female ratio was 1:2. The children underwent 
repairs of congenital heart defects. 
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likely that the inhibitor was a protein. For this reason, 
and the fact that any non-proteinaceous inhibitors would be 
diluted equally with the plasma proteins, the tests of 
surfactant inhibition were performed with respect to the 
total protein mixed with the surfactant. ie. Total protein 
was used as a simple measure to standardize for 
inhomogeneous concentrations or dilutions among individual 
samples. Also, the phospholipid content varied by 
approximately 12% between surfactant suspensions. The 
variation in the amount of plasma mixed with the constant 
surface load of surfactant was expressed in terms of mg of 
total protein/ug of phospholipid. For convenience of 
statistical calculations, the ratio, mg total protein/ug PL, 
was multiplied by a factor of 10 to bring the numbers in the 
range 0 to 1.25. ie. The values of mg total protein/ug PL 
were in the range 0 to 0.125, were multiplied by 10, and 
expressed at 0 to 1.25 with the units, mg protein/ug PL x 
10. 
During the study two suspensions of surfactant were used. 
Both came from the same batch of lyophilized pig lung 
surfactant, harvested on day 1/8/83, and processed in our 
protocol. The resuspensions were performed on different 
days and are denoted sam E and sam F. The method of 
resuspending the lyophilized material using solution #1, a 
glass stirring rod, vortexing and sonication, was the same. 
Aliquots of both were stored at -20 degrees C. Although the 
concentration of surfactant was 2 mg/ml the phospholipid 
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concentrations (taken as 25 times the phosphorus 
concentration) were different. The concentrations were: 
samE, 1.5 mg/ml PL and, sam F, 1.3 mg/ml PL. A likely 
reason for the different phospholipid concentrations was the 
hygroscopic nature of the lyophilized surfactant, and 
differences in water content of the material at the 
different times of resuspension. Surfactant surface loads 
of sam E, 7.4 ug PL, and sam F, 6.5 ug PL (equivalent to 10 
ug surfactant) were used in tests on the surface balance. 
Delta gamma-min, the difference in the surface tensions at 
minimum surface area of the mixture of plasma and surfactant 
and of surfactant alone, was plotted against the total 
protein/phospholipid load on the surface. Regression 
analysis was used to determine if the line of best fit was 
linear. Analysis of variance and an overall F-test of the 
lines of best fit was used to compare the data between 
groups. 
The groups consisted of the different patient populations 
(normal adults, adult patients and child patients) and the 
times when the blood was collected (eg. CPB-1 to -4, pre-
and postpump). The subjects from whom blood was collected 
and tested with sam E were separate from those tested with 
sam F. ie. SamE and sam F tests were not performed on the 
test samples from the same patients. 
A significance level of 0.05 was used. 
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control tests of pump priming solution and dilution 
solution from the pump priming circuit was tested to 
investigate possible effects of heparin and plasticizers. 
This solution contained human albumin, heparin, NaHCO and 
3 
Ringer's lactate. Samples were taken once the solution had 
been circulated in the pump circuit. Tests compared the 
effect on surfactant function of priming solution from the 
pump to that of human albumin alone. There was no 
significant difference between the effects of the two 
solutions, p).25 (Figure 3-l). 
Tests on the effects of dilution were repeated. 
Surfactant was mixed with varying quantities of solution #l 
which approximated the range of volumes used when adding the 
plasma. These volumes were greater than those used in the 
previous tests of 2:1, 1:1, 1:2 v:v, because hemodilution 
techniques were used in the CPB procedures. ie. The plasma 
protein concentrations were decreased by dilution and in 
order to test the same range of protein loads on the surface 
more plasma volume was required. Only one test of dilution 
with sam E was performed because supply was depleted. Sam 
G, 1.5 ug PL/ul, surface load, 7.5 ug PL, was used in 
additional tests of the effect of dilution. 
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3 .3 Results 
The data from the plots of all groups were best described 
by linear regression except for one group, the adult CPB-2, 
sam F group. The t-value for the quadratic term in the 
quadratic regression was significant (p=.002), implying that 
the line of best fit was not linear. The finding of one 
non-linear line of best fit seemed out of context when all 
the other lines of best fit were linear. A sound practical, 
chemical or physiologic reason for such an event was not 
apparent. As well the linear regression described the data 
for this group with a correlation coefficient which compared 
well with those of the other groups (Table 3-1). Thus, the 
linear regression line of best fit was used in comparisons 
involving the group adult CPB-2, sam F. Table 3-1 gives the 
parameters of the lines of best fit of the test groups. 
Of the adult patients entered in the study, none developed 
ARDS. Of the child patients, one developed RDS following 
CPB and subsequently died. 
The effect of CPB on potential surfactant inhibitors in 
plasma was determined by three sets of comparisons between 
pre- and postpump groups in adults and children. There was 
internal control in each comparison, ie. the pre- and 
postpump groups used blood samples from the same group of 
patients. The first compared the adult CPB plasma groups 1 
to 4, using samE (Figure 3-2). The second compared the 
adult CPB plasma groups 1 to 4, using sam F (Figure 3-3). 
Again, the patients from whom blood was collected and tested 
68 
~ith sam E were not the same patients from whom blood was 
collected and tested with sam F. The third test compared 
the child CPB groups pre- and postpump plasma, using sam F 
(Figure 3-4). There was no significant difference between 
the groups, p).25, for all three comparisons. Increased 
inhibition was not seen in the plasma of adults taken 20-24 
hours after CPB, a time when postoperative pulmonary 
complications are usually apparent. Thus no significant 
increase in inhibition by plasma as a consequence of CPB was 
seen in either children or adults. 
To investigate possible differences between adult patients 
and child patients, the effects of surfactant inhibition by 
the plasma sampled from these groups were compared in three 
tests. Comparisons were made i) between the adult CPB-2 and 
the child prepump groups, ii) between the adult CPB-3 and 
the child postpump groups, and iii) between the pooled data 
of the adult CPB groups 1 to 4, and the pooled data of the 
child pre- and postpump groups. Previous comparisons had 
shown that there was no difference among the adult CPB 
groups 1 to 4, or between the child pre- and postpump 
groups. The validity of comparing the adult and child 
patients using the pooled data was checked using a test of 
variance. The variance of the data was estimated to be the 
same for all of the groups tested. 
There was a significant difference between the adult CPB-2 
plasma, sam F, n=4, group and the child prepump plasma, sam 
F, group, n=S, .025)p).01. The data for the adult CPB-2 
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group showed slightly greater inhibition than that for the 
child prepump group. The difference was due mainly to a 
difference in elevation (y-intercept) and not to a 
difference in slope (Table 3-1). There was no significant 
difference between the adult CPB-3 plasma, sam F, n=4, group 
and the child postpump plasma, sam F, group, n=5, .10)p).05. 
There was a significant difference between the pooled data 
from the adult CPB groups 1 to 4, plasma, sam F, n=14, and 
the pooled data from the child pre- and postpump groups, 
plasma, sam F, n=10, p(.01. Again slightly more inhibition 
was seen with the adult patients than with the child 
patients (Figure 3-5). 
Possible differences in the effects of plasma and sera on 
surfactant inhibitors in plasma was investigated by 
comparing plasma and sera in the normal adult groups for sam 
E and sam F. In both comparisons (plasma vs sera, sam E . , 
plasma vs sera, sam F) there was a significant difference, 
p(.0005. Plasma was more inhibitory than sera in both 
comparisons (Figures 3-6 and 3-7). The differences were in 
the slopes of the regression lines for both comparisons. 
To investigate the possibility of differences between 
patients and normals, comparisons were made using an 
individual CPB group, CPB-1, for the comparison of adult 
normal and adult CPB patient plasma. The CPB-1 group was 
chosen because the patients at this time would not have been 
subjected to anesthetic or surgery. Comparisons were also 
made using the pooled data from the adult CPB-1 to -4 
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groups, justified by a test of variance for the data of the 
groups. 
There was no difference between the group normal adult 
plasma, samE, n=8, and the group adult CPB-1 plasma, sam E, 
n=S, .25)p).10. There was also no difference between the 
group normal adult plasma, sam E, n=8, and the pooled data 
from the adult CPB-1 to -4 plasma, sam E, n=19, p).25 
(Figure 3-8). In the respective tests using sam F, there 
was no difference between the group normal adult plasma, sam 
F, n=3, and the group adult CPB-1, plasma, sam F, n=2, 
.10)p).05. However, there was a difference between the 
group normal adult plasma, sam F, n=3, and the collective 
adult CPB 1 to 4 plasma, sam F, n=14, p(.OOS (Figure 3-9). 
Here, the plasma from the patients showed more inhibition 
than that from the normal adults, and the difference was in 
the slopes of the regression lines. 
Possible differences between normal adults and adult 
patients might exist in the sera. Sera was prepared from 
the adult patients only in the CPB-1 and CPB-2 groups. The 
pooled n for the data of tests with sera collected from 
the adult patients was five for the sam E group, and four 
for the sam F group. Here, the pooled n equaled the 
actual number of patients. 
There was a significant difference between sera from the 
group normal adults, samE, n=8, and the group adult 
patients CPB 1 and 2, samE, n=S, p(.01. In these sam E 
sera tests, the patients showed more inhibition than did 
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normals (Figure 3-10). The difference was in the slopes of 
the linear regression lines. There was also a significant 
difference between sera from the group normal adults, sam F, 
n=3, and the group adult patients CPB 1 and 2, sam F, n=4, 
p<.OOS. However, in these sam F - sera tests, the normals 
showed more inhibition than did the patients (Figure 3-11). 
Here, the difference was in the elevations of the linear 
regressions. 
In the above comparisons, the sam E tests were conducted 
separately from the sam F tests. There was a 12% difference 
in the surface load of phospholipid (samE, 7.4 ug PL; sam 
F, 6.5 ug PL). To test for differences in the effects of 
plasma and sera on the two surfactant suspensions, the data 
from the adult normal groups were used. There was a 
significant difference between the normal adult plasma group 
using samE and that using sam F, p<.OOOS (Figure 3-12). 
There was also a significant difference between the normal 
adult sera group using samE and that using sam F, p<.OOOS 
(Figure 3-13). In both comparisons the sam F tests showed 
more inhibition than did the samE tests, with the 
differences accounted for by differences in elevation of the 
regression lines. 
Table 3-1 gives the parameters of the lines of best fit of 
the test groups, summarizing the data found in the preceding 
plots of delta gamma-min vs total protein/PL (mg/ug x 10). 
The number of patients involved is given by n The 
y-intercept of the lines of best fit is given by a and the 
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slope of the lines of best fit is given by "b". The 
correlation coefficient of the lines of best fit is given by 
2 
"r and is an indicator of the fit of the line to the 
data. Rough comparisons of the groups may be made on the 
basis of the a "b" and n values. Actual statistical 
probabilities for comparisons have been given above in the 
text, and also are summarized in Table 3-2. 
85 
Table 3-1: Parameters of the lines of best fit 
of the test groups 
2 
n a b r 
Normals, sam E 
plasma 8 0.4 12.1 .67 
serum 8 2.2 4.7 .38 
Normals, sam F 
plasma 3 6.1 12.4 .96 
serum 3 8.2 5.6 .69 
Adult CPB plasma, sam E 
CPB-1 5 3.8 8.8 • 3 8 
CPB-2 4 0.7 13.6 .57 
CPB-3 5 0.7 11.0 .41 
CPB-4 5 1.9 9.9 .48 
CPB-all 1.7 10.9 .46 
Adult CPB plasma, sam F 
CPB-1 2 3.3 18.1 .91 
CPB-2 4 5.8 17.5 .90 
CPB-3 4 5.7 15.1 . 91 
CPB-4 4 4.5 18.0 .84 
CPB-all 5.1 17.0 .87 
Adult CPB-1 or -2 serum 
sam E 5 3.0 8.3 .33 
sam F 4 0.7 11.7 . 9 0 
Child CPB plasma, sam F 
prepump 5 1.9 18.0 .74 
postpump 5 5.0 12.8 .67 
overall 3.8 14.9 .69 
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Table 3-2: Summary of Comparisons 
comparison significant difference p-value 
----
---------------------------------------------------
adult CPB plasma, sam E, 
groups 1 to 4 
adult CPB plasma, sam F, 
groups 1 to 4 
child CPB plasma, sam F, 
pre- vs postpump 
no 
no 
no 
>.25 
>.25 
>.25 
----------------------------------------------------
adult CPB-2 vs child prepump, 
plasma, sam F 
adult CPB-3 vs child postpump, 
plasma, sam F 
adult patients (CPB-1 to -4) 
vs child patients (pre- and postpump), 
plasma, sam F 
adult normals vs patients 
(CPB-1 to -4),plasma, samE 
adult normals vs CPB-1, 
plasma, sam E 
adult normals vs patients 
(CPB-1 to -4), sam F 
adult normals vs CPB-1, 
plasma, sam F 
adult normals vs patients 
(CPB-1 or -2), sera, samE 
adult normals 
(CPB-1 or-2), 
vs patients 
sera, sam F 
yes <.01 
no >.05 
yes <.01 
no >.25 
no >.10 
yes <.01 
no >.05 
yes < .. 01 
yes <.01 
87 
Table 3-2 (continued) 
Comparison significant difference p-value 
-------------------------------------------------------
plasma vs sera, normal adults, yes <.01 
sam E 
plasma vs sera, normal adults, yes <.01 
sam F 
-----------------------------------------------------
sam E vs sam F, normal adults, 
plasma 
sam E vs sam F, normal adults, 
sera 
yes 
yes 
<.01 
<.Ol 
The effect of prolonged bypass was examined in one child 
patient, who subsequently died of cardiac and pulmonary 
complications. RDS was evident in this patient 
postoperatively. There was no obvious difference between 
samples taken before bypass, at pump time one and one-half 
hours and at pump time 3 hours (Figure 3-14). 
There was no effect of dilution when sam E was diluted 
with 20 ul of solution #1. This is a ratio of 
surfactant:solution #1, 1:4 v:v. There was a slight effect 
of dilution on surfactant ability to reach low surface 
tensions with sam G (Figure 3-15). Inhibition was seen in 
the higher ranges of dilution at volumes greater than 10 ul. 
Delta gamma-min increased linearly with increasing dilution. 
Note that sam G was not used in the tests of surfactant 
inhibition by plasma or sera. 
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3.4 Discussion 
Cardiopulmonary bypass is a known etiologic agent of acute 
lung injury, and although the incidence of respiratory 
distress syndrome following operations involving CPB is 
small in elective adult cardiac surgery today, RDS remains a 
significant complication in pediatric cases and cases 
involving prolonged bypass. CPB provided a setting where an 
inflammatory response induced in the blood might produce or 
increase levels of potential circulating inhibitors. The 
inflammatory response is a mechanism whereby blood-air 
membranes could be injured, and plasma constituents could 
enter into the alveoli. The pathophysiologic 
characteristics of acute lung injury and the clinical 
characteristics of RDS following CPB are similar to those of 
ARDS. CPB is included in the long list of etiologic factors 
of ARDS. 
The literature did not present a clear view of the effect 
of normal blood or plasma proteins on surfactant function, 
or of CPB on surfactant inhibitors in plasma. Normal blood 
was found to inhibit surfactant on the surface balance 
(Mandelbaum & Giammona, 1964; Tierney & Johnson, 1965). In 
contrast, Gardner et al (1962) found that surfactant was not 
inhibited by blood from normal individuals. And, Tierney & 
Johnson (1965) found that blood from normals injected into a 
hypophase solution of surfactant on the surface balance did 
not inhibit surfactant. Test conditions were noted to vary 
between these investigations. Blood pumped in vitro through 
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oxygenator circuits with no tissue contact was observed to 
inhibit surfactant in tests on the surface balance (Gardner 
et al, 1962; Mandelbaum & Giammona, 1964). However, blood 
taken from dogs after five hours of CPB did not inhibit 
surfactant when tested under the same conditions (Mandelbaum 
& Giammona, 1964). 
It was suggested that the timing of surfactant dysfunction 
with hemodilution techniques was delayed by 15-24 hours 
following CPB (Camishion et al, 1968; Hepps et al 1963), 
whereas the maximum injury to the lung occured at 2 hours 
following CPB (Royston et al, 1983). No previous 
investigation had studied surfactant inhibition in human 
subjects undergoing CPB. 
In this study, conditions for testing plasma-surfactant 
mixtures were defined. The model of plasma-surfactant 
interaction used in the study placed both plasma and 
surfactant on the surface of a hypophase solution on the 
surface balance. Tests using this assay would correspond to 
the situation in the alveolus where both plasma and 
surfactant would exist at the air-water interface. 
In plasma-surfactant tests on the surface balance under 
these test conditions, plasma from the adult normal groups, 
all the adult patient groups and the child patient groups 
inhibited surfactant in a direct relationship between delta 
gamma-min and total protein load (except the adult group 
CPB-2, sam F). 
The effect of CPB on the production of plasma inhibitors 
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or the increase in levels of inhibitors was studied. In 
consideration of a possible timing effect, postpump samples 
~ere taken in the adult patients at two times. The first 
was immediately after CPB, just before lung injury may be 
maximum, and the second at 20-24 hours after CPB, when 
postpump pulmonary complications would be apparent. 
Hemodilution was used in all cases of CPB in the study. 
No difference was seen comparing prepump and postpump 
groups in adults or children. There was no increased 
inhibition in samples taken at either of the postpump times 
in the adult patients. The tests were internally 
controlled, ie. pre- and postpump blood was taken from the 
same patients. There was no additional effect of heparin or 
possible plasticizers. 
Increased inhibitors may have been produced by the CPB but 
they may not have been detected in this study. Possible 
reasons include decay of the inhibitor between the time of 
sampling and the time of testing, and the presence of 
inhibitors in the airways but not in plasma. For example, 
prostaglandins and related compounds have half-lives of 
minutes and phospholipases may be present locally in the 
airways. 
CPB patient plasma was significantly different between 
child and adult plasma groups, sam F, in two comparisons. 
These were the comparisons of i) the adult CPB-2 group and 
the child prepump group, and ii) the pooled data from the 
adult CPB groups l to 4 and the pooled data from the child 
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CPB pre- and postpump groups. In both of these comparisons 
the adult patients showed slightly more inhibition than did 
the child patients. However in another comparison of adult 
patients and child patients, adult CPB-3 plasma, sam F, vs 
child postpump plasma, sam F, a significant difference was 
not seen. This result certainly does not explain the 
observation that children have more lung dysfunction 
following CPB than do adults. 
One case of prolonged bypass was examined. No obvious 
increase in inhibition was seen in the prolonged pump time 
of 3 hours. This may reflect the lack of increase in 
inhibition seen with blood exposed to CPB in general. 
Comparisons were made between adult normals and adult CPB 
patients. No conclusive difference between the effects of 
normal and patient blood was seen. There was no difference 
between normal adults and adult patients in tests using 
plasma in three of four tests. One comparison, however, of 
plasma taken from normal adults and adult patients showed 
more inhibition with patients than with normals. There were 
differences between normal adults and adult patients using 
sera, but the differences were in the opposite direction when 
tests were done with the two surfactant preparations. If 
patients did have some increased surfactant inhibitor in 
their blood, it might be speculated that the elevated levels 
may be a result of stress. The increased catecholamines 
might elevate fibrinogen levels and other acute phase 
proteins or increase levels of free fatty acids or glucose. 
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The stress state might then predispose the patient to 
surfactant inhibition if there was damage to the lung 
blood-air membranes. 
Results of tests for plasma and sera from normals using 
sam E were different from those of the respective tests 
using sam F. There are two possible explanations. The 
first is that the phospholipid/protein ratio may be critical 
to the ability of the surfactant to reach low surface 
tensions. With the lower surfactant phospholipid surface 
load used in tests with sam F, 6.5 ug PL, more inhibition 
was seen for the range of protein surface load tested. 
the higher 
7.4 ug PL, 
surfactant surface load used in tests with 
less inhibition was seen. Note again that 
surface loads of sam E and sam F differed only by 12%. 
With 
sam E, 
the 
The 
second possibility is that some unknown factor may have been 
present in the sam F suspension to inhibit its activity, 
even though the method of suspending the lyophilized pig 
lung surfactant was the same for both, both originated from 
the same batch of processed lung washings, and the minimum 
surface tensions of both sam E and sam F suspensions were 
the same (< 5 mN/m). The possibility that dilutional 
effects may account for differences did not seem applicable 
for this range of dilution. ie. To dilute sam E to the 
concentration of sam F would involve adding less than one ul 
of diluting saline to the surface load of surfactant. 
Scatter in the data occured even though the experiments 
were performed under well-defined conditions. The scatter 
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perhaps is a reflection of the varied findings in the 
literature. Variability may be found in human blood 
samples, in the preparation of surfactant from lung lavage 
and the efficacy of the surfactant preparation to reach low 
surface tensions, in methods of blood collection, in test 
conditions of mixing the surfactant and potential inhibitor 
(blood, plasma or protein), and in conditions of testing the 
mixtures on the surface balance. 
Trurnit (1960) studied proteins at the air-water 
interface. A glass rod of specified length and diameter was 
used to place the protein solution onto the surface of the 
hypophase solution. It was suggested that with this method 
more protein adsorbed to the air-water interface than with a 
droplet technique. It was stated that as much as 60% of the 
protein was lost into the hypophase using a droplet 
technique. However, when Tabak & Notter (1977) tested the 
interaction of proteins and DPPC at the air-water interface 
using the glass rod technique, albumin and fibrinogen did 
not inhibit DPPC from reaching low surface tension on 
compression. It was noted that the DPPC was added to the 
surface before the protein. Taylor & Abrams (1966) and 
Miyahara (1969) used the glass rod to spread mixtures of the 
surfactant and protein onto the surface. However while 
Miyahara reported that fibrinogen, albumin and the globulins 
all inhibited surfactant, Taylor & Abrams (1966) found that 
fibrinogen prevented surfactant from reaching low surface 
tensions, but that albumin and the globulins did not. Thus 
96 
the glass rod technique did not eliminate inconsistencies in 
the literature data. In the experiments of this thesis, 
some variability may have arisen from variable amounts of 
protein adsorbing to the surface using the droplet 
technique, and variable loss of protein onto the side walls 
of the trough. 
Other authors tested surfactant extracts and blood on the 
surface balance (Gardner et al, 1962; Mandelbaum & Giammona, 
1964; Tierney & Johnson, 1965), but used the extracts of 
lung minces as the hypophase solution. Surfactant would be 
needed in much larger quantities using this method compared 
with the method using a hypophase of saline which was 
employed in the experiments of this study. Rufer & Stolz 
(1969) used a protein solution as the hypophase and layered 
the surfactant onto the surface with an alcohol spreading 
solution. These different methods may account for some of 
the variability in the results of the literature. 
The effects of dilution were variable. In the one test 
using sam E there was no effect of dilution to 1:4 v:v (20 
ul of solution #1). In the previous tests of dilution with 
sam C, there was no effect of dilution to 1:2 v:v. With sam 
G however, inhibition was seen at dilutions greater than 1:2 
v:v, 10 ul. The lipid aggregate structures in surfactant 
would be preserved in this range of concentration. This 
degree of dilution would not disaggregate these structures 
-6 
because the concentration of lipid, at least 10 M, would 
still be much greater than the critical micellar 
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concentration, approximately 10 M. It was noted that sam 
G had been stored in lyophilized form at -20 degrees C for a 
longer period of time (approximately 8 months) compared with 
samE (3 months) and sam F (4 months). The effect of 
prolonged storage time on the surfactant was not studied. 
If dilution did increase the degree of inhibition in the 
tests using samE and sam F, this would be important 
particularly for the postpump hemodiluted samples. The 
corrected values for delta gamma-min would show less 
inhibition than the indicated values, implying that the 
postpump samples were less inhibitory than indicated. In 
any event this would not deter from the conclusion that CPB 
did not increase inhibition. 
In conclusion, the data are consistent with the 
possibility that plasma components entering the airspaces 
through leaking lung membranes may inhibit surfactant from 
proper function, and may contribute to the collapse and 
edema of the lungs seen in the ARDS of any etiology. CPB 
did not increase the levels of plasma inhibitors in the 
assay used in this study. 
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Chapter 4 
Nature of the inhibition 
4.1 Characterization of the inhibitor 
4.1.1 Introduction 
The literature has suggested that components in the plasma 
may affect surfactant function. These include proteins, 
free fatty acids and cholesterol. Most of the literature 
articles reviewed have investigated the protein fractions of 
plasma as the inhibitory component (Taylor & Abrams, 1966; 
Balis 
Rufer 
et al, 1971; Miyahara, 
& Stolz, 1969; Tierney 
1969; Tabak & Notter, 1977; 
& Johnson, 1965). Tierney & 
Johnson (1965) also tested the effects of cholesterol and 
oleic acid on surface films of rabbit lung surfactant 
prepared from extracts and found that the minimum surface 
tension was increased. Gardner et al (1962) suggested that 
blood which had been circulated through a CPB pump inhibited 
surfactant by the release of free lipids following the 
protein denaturation caused by the pump. Hallman et al 
(1982) found that the lung surfactant-deficient states of 
RDS in newborns and in adults were associated with 
abnormalities in the negatively-charged lipids with a high 
ratio of PI/PG. 
, 
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In the introductory section, "Surfactant: component 
function, physical properties and structure", it was 
presented that the surface film must contain a high 
proportion of DPPC because low minimum surface tension was 
not achievable by other compounds at 37 degrees C. The 
addition of any substance to the surfactant surface layer 
might prevent the achievement of low surface tension by 
displacing DPPC from the surface or by interfering with the 
phospholipid monolayer packing on compression of the 
surface. 
Recently Ikegami et al (1983) and Jobe et al (1983) 
described a specific surfactant inhibitor in the airways of 
premature infants and lambs with RDS. This was associated 
with leaking lung membranes as shown by a high rate of 
appearance in the airways of radioactively-labelled albumin 
which had been given intravenously. The specific inhibitor 
was tested using the pulsating bubble apparatus (the dynamic 
alveolar model) after Nozaki (1970). The inhibitor was 
isolated from airway washings. The washings were 
centrifuged on 0.7M sucrose. The material floating on the 
sucrose was pelleted with a second centrifugation. The 
specific surfactant inhibitor was isoiated from the 
supernatant from this second centrifugation by successive 
polyethylene glycol (PEG) precipitations. The specific 
inhibitor was found in the fraction precipitating between 25 
and 50% PEG, the PEG 50% fraction. It was found to increase 
minimum surface tension to large degrees with only small 
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amounts of protein relative to surfactant. It was indicated 
that the protein isolated by PEG fractionation was greater 
than 20 times more inhibitory than the proteins of the 
airway washings as a whole. The specific inhibitor was 
partially characterized as a substance with MW > 12,000. It 
was not inactivated by boiling or lipid solvent extraction 
techniques. 
protease. 
It was completely inactivated by an unspecified 
In the studies of this thesis plasma did inhibit 
surfactant from reaching low minimum surface tension. The 
following questions were asked: Was the inhibitor in plasma 
a protein? and, Was the specific surfactant inhibitor 
described by Ikegami et al (1983) and Jobe et al (1983) 
present in plasma? 
Experiments were performed i) to test if the inhibitor was 
a protein, ii) to look for the Ikegami-Jobe specific 
surfactant inhibitor in plasma, and iii) to compare plasma 
from normals with plasma from patients using the 
fractionated components of plasma. 
4.1.2 Plasma treatments 
Methods 
Plasma, which was anticoagulated with heparin, was taken 
from normals and patients (hemodiluted post-pump blood). 
The plasma was treated with a general protease, proteinase K 
(Sigma P-0390 lot 14F-0142). This enzyme, prepared from the 
fungus, Tritirachium album, is reported to have wide 
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spectrum activity, cleaving the peptide bonds adjacent to 
the carboxyl groups of aliphatic and aromatic amino acids 
with blocked alpha-amino groups. The proteinase was added 
to the plasma in a ratio of 50 ug enzyme:50 mg plasma 
protein (1:1000 by weight; personal communication from Dr. 
w. Davidson~ Department of Biochemistry~ Memorial University 
of Newfoundland), and incubated overnight at 37 degrees C. 
A clot was formed. The supernatant (Brinkmann Instruments 
centrifuge 3200 for Eppendorf centrifuge tubes; 10 min at 
12,000 gav) was tested for surfactant inhibition and was 
analysed using polyacrylamide gel electrophoresis. 
0.5 ml portions of the plasma from the same normals and 
patients were diluted with solution #1, 1:10 v:v~ and placed 
in a bath of boiling water. The supernatant (IEC bench-top 
centrifuge; setting = 6. 
' 
10 min) was used to test for 
surfactant inhibition and was analysed by polyacrylamide gel 
electrophoresis. It was noted that whole plasma when boiled 
yielded a coagulated solid with no supernatant. This was 
not suitable for testing. 
0.5 ml portions of the plasma from the same normals and 
patients were dialysed with a 12,000 MW exclusion membrane 
against solution #1 in the Eppendorf centrifuge tubes 
(appendix Figure A-2). The volume of the bath was 500 ml 
and was changed two times. The dialysis proceeded overnight 
at 4 degrees C and with constant stirring. The dialysed 
plasma was used to test for surfactant inhibition and was 
analysed using polyacrylamide gel electrophoresis~ 
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surface studies were performed on mixtures of surfactant 
(the sam F suspension) and treated plasma or plasma 
fractions as described previously. Polyacrylamide gel 
electrophoresis was run with the aid of Dr. W.Davidson, 
Department of Biochemistry, MUN (appendix A.9). 
Results 
It was observed that all of the treated plasma samples 
inhibited the surfactant from reaching low surface tensions 
(Table 4-1). Figures 4-1 and 4-1(a) show examples of the 
polyacrylamide gel electrophoresis patterns of the treated 
plasma samples. Comparing the values of delta gamma-min at 
protein/PL = 0.77 (mg/ug x 10) for normals and patients, 
there were no large differences between the untreated, 
proteinase treated and dialysed samples. The values of 
delta gamma-min were in the range 12 to 17 mN/m, which most 
likely is within experimental error under these test 
conditions. 
The effects of dilution were not tested with sam F because 
of lack of supply. Inferences from the previous data on 
dilutional effects indicated that surfactant might be 
inhibited by dilution if the volumes of the test salliple 
added to the surfactant was greater than 10 ul. No 
conclusions about dilution effects were made from 
comparisons of the hemodiluted patient samples and the 
plasma from normals. 
The effects of dilution were particularly relevant to the 
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supernatants of the boiled plasma samples. The protein 
content of these supernatants were low relative to untreated 
plasma. Tests at the protein/PL range of 0.77 (mg/ug x 10) 
were not performed because very large volumes would be 
needed. The observed values of delta gamma-min for the 
supernatants of the boiled plasma samples tested at 0.1 
(mg/ug x 10) were likely appropriate for the low amount of 
protein and the volumes employed (15-20 ul). That no higher 
values of delta gamma-min were observed might suggest that 
no other inhibitors were present after boiling, ie. free 
fatty acids, cholesterol, etc. Protein staining was not 
seen following polyacrylamide gel electrophoresis of these 
boiled samples, likely because the concentration of protein 
was too low (Figures 4-1, 4-1 (a)). The dialysed samples 
This showed inhibition comparable to the untreated plasma. 
indicated that the inhibitors had MW > 12,000 daltons. 
Polyacrylamide gel electrophoretic patterns were similar to 
those of untreated plasma (Figures 4-1, 4-1(a)). 
The samples treated with the proteinase also showed 
inhibition similar to untreated plasma. This was unexpected 
in our view that the inhibitors were proteins. The 
possibilities were: i) the inhibitory effect seen was due 
to smaller peptides, or ii) the enzyme did not work. In 
fact, the polyacrylamide gel electrophoretic patterns did 
not show any smearing of bands in the protease-treated 
samples which might be expected after general proteolytic 
activity (Figures 4-1, 4-1(a)). Possible explanations for 
Table 4-1: 
T.Protein/PL 
(mg/ug x 10) 
untreated 0.77 
proteinase 0.77 
dialysed 0.77 
boiled 0.1 
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Tests of treated plasma using 
sam F 7.8 ug PL 
Delta gamma-min, mN/m 
normals 
(n=2) 
13.5 +0.5 
( 7 & 8 ul) * 
12 +0 
(7 & 8 ul) 
16.5 +2.5 
(9 & ro ul) 
3 +0 
(1S & 15 ul) 
patients 
(n=2) 
15 +2 
(13 & 14 ul) 
13 +1 
(13 & l4 ul) 
16.5 +.5 
(15 &-17 ul) 
2.5 +1.5 
(15 & 20 ul) 
*Volumes of plasma sample applied to the surface 
lack of proteinase activity are i) proteinase autolysis and 
autodigestion, and ii) the presence of natural antiproteases 
in plasma. We did not further pursue investigation of the 
proteinase due to expense and time restrictions. 
There was no appreciable difference between the treated 
plasma taken from normals and patients in the small number 
of samples tested. 
In summary, the data were consistent with the 
interpretation that the inhibitors present in plasma were 
1 2 3 
Figure 4-1: 
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Lanes 1,10 
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Lane 8 
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untreated 
F igure 4-la 
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proteinase PEG 50% 
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Polyacrylamide gel electrophoresis of 
the treated plasma samples and 
the 50% PEG fraction 
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proteins. 
unlikely. 
Inhibition by other plasma components seemed 
4.1.3 Polyethylene glycol fractionation 
Polyethylene glycol (PEG) fractionation of plasma proteins 
was used to investigate two potential effects. First, it 
was used to determine if any possible differences between 
the plasma of normals and patients could be localized to 
different plasma protein fractions, eg. fractions containing 
globulins, fibrinogen, albumin. Second, an attempt was made 
to find the specific surfactant inhibitor of Ikegami and 
Jobe (Ikegami et al, 1983; Jobe et al, 1983) in the plasma 
of normal adults and adult patients. 
PEG is a high molecular weight polyalcohol which 
chaotropically alters the activity of the water surrounding 
proteins, hence causing precipitation. PEG with an average 
MW of 3350 was used (after Ikegami et al, 1983). Solutions 
with the 3350 MW polymer have relatively low viscosity, and 
are reported to cause no denaturation of plasma proteins at 
room temperature. Manipulation at room temperature is 
advantageous in comparison to the manipulations at freezing 
temperatures required by fractionation with ethanol and 
ammonium-sulfate (Cohn, McMeekin, Oncley, Newell & Hughes, 
1940; Cohn, Gurd, Surgenor, Barnes, Brown, Derouaux, 
Gillespie, Kahnt, Lever, Liu, Mittelman, Mouton, Schmid & 
Uroma, 1950; Edsall & Anson, 1947). The PEG concentrations 
and pH changes used were outlined by Ikegami et al (1983). 
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The first fraction, the precipitate obtained at a PEG 
concentration of 17%, pH 7.0 (PEG 17%), should contain as 
major components fibrinogen and the globulins. The second 
fraction, the material precipitated between 17 and 25% PEG, 
pH 5.4 (PEG 25%), was expected to contain albumin as the 
major component. The last fraction, the material 
precipitated between 25 and 50% PEG, pH 5.4 (PEG 50%), was 
expected to contain the specific surfactant inhibitor 
(Ikegami et al, 1983; Polson, Potgieter, Largier, Mears & 
Joubert, 1964). 
An important consideration was the likely inhibition of 
surfactant by the PEG. 
precipitated protein. 
There would be residual PEG with the 
It was asked: Could the inhibitory 
component of the PEG be accounted for and subtracted out of 
the total inhibition, leaving only the inhibition due to the 
protein? 
proteins? 
Or, must the residual PEG be removed from the 
The PEG fractionation procedure is described in appendix 
A.10. Tests of surfactant inhibition were conducted on the 
surface balance with the same methods used previously. 
PEG was found to inhibit surfactant from reaching low 
minimum surface tensions. The degree of inhibition varied 
directly with the amount of PEG. The relationship, delta 
gamma-min = 1.91 + 0.27 [ug PEG/ug PL] describes the data 
given in appendix A.ll for the line of best fit for a plot 
of delta gamma-min vs PEG/PL. The concentration of PEG 
could be estimated using the refractive index of the 
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solution. From the data given in tables in appendix A.ll it 
was found that the refractive index of a solution of PEG and 
bovine serum albumin (BSA) was the sum of the refractive 
indices of the BSA and PEG components in solution: 
RI(BSA) -.36 + 0.1 [mg BSA/ml] 
RI(PEG) = 0.8 [g PEG/dl] 
RI(total) = RI(BSA) + RI(PEG) 
Once the concentration of PEG in the protein fraction was 
determined by refractive index the contribution to the 
inhibition caused by that amount of PEG could be calculated. 
The effect of PEG on the total inhibition was then 
subtracted from the total leaving the inhibition due to the 
protein. In this way, the inhibition due to the protein 
alone was determined. Addition of the delta gamma-min due 
to protein and that due to PEG was assumed to give the total 
delta gamma-min. 
In Table 4-2, "NF'' denotes plasma taken from a normal 
individual and "TH", that from one patient. The PEG 
fractions were the precipitates obtained at the PEG 
concentrations 17%, 17-25% and 25-50%. The determination of 
the concentration of PEG was based on the concentration of 
protein determined by the Biuret method, and observations of 
the refractive indices of solutions of BSA and PEG as 
outlined previously. The total delta gamma-min were 
observed data. The determination of the contribution to the 
total delta gamma-min by the PEG was based on the observed 
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delta gamma-min for the PEG solution. The determination of 
the contribution to the total delta gamma-min of the protein 
~as based on the assumed relationship, total delta gamma-min 
= delta gamma-min due to PEG + delta gamma-min due to 
protein. 
It was found that the calculated inhibition due to the 
residual PEG was much greater than the observed total 
inhibition of the protein-PEG solution in some cases (Table 
4-2). Attempts were made to remove the PEG from the protein 
since the inhibition due to the residual PEG could not be 
accounted for by the above methods and could not be ignored. 
Attempts to remove the PEG by dialysis with an 8,000 MW 
exclusion membrane failed. It was postulated that the PEG, 
MW 3350, would form micelles which would not be able to 
penetrate the membrane. Next, ethanol was used to 
precipitate the protein, leaving the PEG still dissolved in 
the ethanol. The method is described in the appendix A.l2. 
Unfortunately a low yield of protein was recovered following 
the ethanol precipitation, eg. 59% of the PEG 17% fraction, 
and 9% of the PEG 25% fraction. The precipitated protein 
also contained residual PEG. The presence of PEG was tested 
by adding one drop of the protein solution to 5 ml of 
Nessler's reagent (Polson et al, 1964). The formation of a 
white precipitate indicated the presence of at least 0.01% 
PEG. 
The PEG SO% fraction was analysed using polyacrylamide gel 
electrophoresis. Only small quantities of protein had been 
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Table 4-2: Polyethylene glycol (PEG) fractions 
delta gamma-min, mN/m 
total protein/PL total PEG protein 
(mg/ug X 10) 
NF 17% .05 9.0 4.0 5.0 
[PEG] = .12 12.4 7.0 5.4 
29 mg/ml .23 13.5 12.1 1.4 
.46 14.7 22.3 - 7. 6 
.69 15.8 32.5 -16.7 
TM 17% .03 2.3 3.8 - 1.5 
[PEG] = • 0 5 13.5 5.7 7. 8 
55 mg/ml .13 13.5 11.4 2. 1 
.51 13.5 40.0 -26.5 
NF 25% .09 13.3 6.6 6.7 
[PEG] = .19 15.6 11.3 4.3 
68 mg/ml .39 24.4 2 0. 7 3.7 
.76 25.6 39.5 -13.9 
TM 25% .08 10.2 7. 7 2.5 
[PEG] = • 15 13.5 13.5 0 
167 mg/ml .39 20.3 3 0. 8 -10.5 
.77 21.5 59.7 -38.2 
NF 50% .002 7.0 6.7 0.3 
[PEG] = .003 11.3 11.5 - 0.2 
138 mg/ml .008 12.2 2 5. 8 -13.6 
.017 14.8 49.7 -34.9 
.033 17.4 97.4 -80.0 
TM 50% .004 2. 3 5.4 - 3.1 
[PEG] = .008 7.9 9.0 - 1.1 
102 mg/ml .013 13.5 12.5 1.0 
.021 16.9 19.6 - 2.7 
.042 24.8 37.2 -12.4 
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recovered. Only one faint band was seen, and this band had 
comparable electrophoretic mobility to albumin. The 
possibilities are that i) there was no Ikegami-Jobe specific 
surfactant inhibitor present in adult plasma or that 
quantities were insufficient to be detected by this assay, 
and ii) the specific inhibitor protein was associated with 
albumin. In a personal communication with Dr. Ikegami it 
was suggested that the specific inhibitor protein was 
present in plasma in small quantities but that it was very 
hard to isolate from albumin. 
PEG fractionation was not pursued further at this time. 
It was felt that time constraints should limit the 
development of methods to separate residual PEG from the 
protein fraction, and the separation of albumin from the 
specific inhibitor. 
4.2 Mechanisms of surfactant inhibition by proteins 
4.2.1 Plasma proteins 
Introduction 
Others have commented on possible mechanisms of plasma 
protein inhibition of surfactant. Balis et al (1971) 
suggested that fibrinogen inactivated surfactant by 
incorporating the surfactant into a clot and so prevented 
access of surfactant to the air-water interface. Serum 
inhibited surfactant from reaching low surface tension but 
this inhibition was reversed by centrifugation to separate 
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the surfactant from the serum proteins. In contrast 
centrifugation of surfactant-fibrinogen mixtures did not 
yield disinhibited surfactant. 
Inhibitory effects of plasma proteins on surfactant were 
found to be variable in the reports of the literature. 
Taylor & Abrams (1966) found that albumin and the globulins 
did not inhibit surfactant~ and Tabak & Notter (1977) found 
that fibrinogen and albumin did not inhibit DPPC. In 
contrast~ Taylor & Abrams (1966) found that fibrinogen did 
inhibit surfactant, and Miyahara (1969) and Rufer & Stolz 
(1969) found that fibrinogen, albumin and the globulins did 
inhibit surfactant. 
In this section tests investigating the effects of the 
individual plasma protein fractions on surfactant were 
performed with the assay used in previous experiments of 
this thesis. 
Methods 
The human plasma proteins, fibrinogen, albumin, and the 
globulins were obtained from a commercial supplier. 
Mixtures of protein and surfactant were placed on the 
surface of a saline hypophase by the droplet technique in 
the same manner as used in previous tests. Because the 
fibrinogen was prepared with citrate which could chelate the 
calcium necessary for surfactant function, the effect of a 
citrate solution was tested on the surfactant (Figure 4-2). 
The citrate content was calculated for each total protein/PL 
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load tested for fibrinogen. Citrate was listed by the 
manufacturers as 15% of the weight of the fibrinogen 
compound. A value for inhibition due to citrate content was 
determined from the line of best fit for citrate effect 
(Figure 4-2). The effect of the citrate contained in each 
total protein/PL load tested for fibrinogen was subtracted 
from the total delta gamma-min of the fibrinogen data. The 
delta gamma-min for the fibrinogen data were corrected for 
the effect of citrate in this manner. 
Results 
Fibrinogen was found to be a potent inhibitor of the 
surfactant (Figure 4-3). High values of delta gamma-min 
were observed at low protein loads. The line of best fit 
was not linear but seemed to asymptotically approach a value 
of delta gamma-min between 25-30 mN/m. This would seem 
reasonable since fibrinogen alone (0.6 mg on the surface) 
was surface active with a minimum surface tension in the 
range of 25-30 mN/n (Figure 4-4). 
Albumin did not have an asymptotic curve in the range of 
protein tested. Rather, the line of best fit was linear in 
this range (Figure 4-3). Surface films of albumin alone 
(1.0 mg on the surface) had minimum surface tensions of 
25-30 mN/m (Figure 4-4). Therefore at high ratios of 
protein to PL, a limiting value of 25-30 mN/m would be 
expected. 
The globulins were found to inhibit surfactant. The 
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asymptotic line seemed to approach a value of 15-20 mN/m 
(Figure 4-5), which is different from those of fibrinogen 
and albumin. Monolayers of pure globulins (0.9 mg on the 
surface) had minimum surface tensions in the range of 15-20 
mN/m (Figure 4-4). 
Plasma and serum were seen previously to inhibit the 
surfactant in a direct relation between delta gamma-min and 
the ratio total protein/phospholipid. Plasma was more 
inhibitory than serum. The increased inhibition of plasma 
may be attributed to the presence of fibrinogen in plasma 
and not serum, and to the high degree of inhibition seen 
with fibrinogen. 
In a hypothetical case where albumin was the only 
inhibitory component of serum, the delta gamma-min of the 
serum effect could be expressed in terms of albumin diluted 
with some non-inhibiting protein. About 50% of the protein 
in serum consists of albumin. If albumin was the only 
inhibitory component of serum then serum should have about 
one-half of the inhibitory effect of albumin on a per mg 
total protein basis. The dashed line of Figure 4-6 
represents the inhibitory effect of albumin diluted by 
one-half with non-inhibiting protein. The line of best fit 
for the serum showed less inhibition than this dashed line. 
This would indicate that the other components of serum may 
be interacting with the albumin to decrease inhibitory 
activity. Simple summation effects of each of the serum 
protein components does not seem to be applicable due to 
some protein-protein interaction (Figure 4-6). 
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4.2.2 Proposed mechanism of inhibition 
Surfactant was inhibited from reaching low surface tensions 
by all of the plasma protein fractions. This inhibition 
was increased as the amount of protein relative to 
phospholipid was increased. 
The ability to reach low surface tension reflects the 
relative amount of DPPC on the surface. Other substances do 
not possess as much ability to lower surface tension at 37 
degrees C. The low surface tension results from the ability 
of DPPC to achieve high packing density and a low free 
energy state on compression at 37 degrees C. Other 
substances like proteins which are surface active, if placed 
in a surface film together with DPPC, may compete for surface 
space. The surface film may therefore contain less DPPC and 
low surface tensions would be prevented on compression. 
The interactions of surfactant and the plama proteins 
fibrinogen, albumin and the globulins were observed to be 
different. The differences in these interactions may be due 
to differences in the hydrophobicity or the degree of 
denaturation of the protein at the surface. Surface films 
of pure proteins are suggested to consist of protein 
unfolded with loss of tertiary structure (Trurnit, 1960; 
Absolom, van Oss, Zingg & Neumann, 1981). The 
hydrophobicity of the proteins in native or denatured forms 
might influence the degree of exclusion of the protein from 
the surface film into the aqueous hypophase on compression. 
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Bigelow (1967) developed a theoretical index of 
hydrophobicity for proteins based on thermodynamic 
measurements of the energies of hydration of the component 
amino acids residues. High values of the hydrophobicity 
index reflect a greater degree of hydrophobicity. There was 
not a good correlation between the observed inhibitory 
effects of the various proteins and the hydrophobicity index 
(Table 4-2). It should be kept in mind that this 
hydrophobicity index is a theoretical number. 
Table 4-3: The hydrophobicity index in kcal/residue 
of various proteins in native conformation 
bovine fibrinogen - 1020 
bovine serum albumin - 1120 
human gamma globulin - 1090 
beta lipoprotein - 1110 
alpha lipovitellin (hen egg) - 1110 
Other factors such as the degree of protein unfolding at 
the surface, the shape of the proteins, their relative 
affinity for the lipid in surfactant and perhaps the 
inherent surface activity of the proteins likely are 
involved in the interaction. 
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4.2.3 Models of mechanisms of protein-surfactant interaction 
on the surface balance 
Introduction 
Varying methods have been used on the surface tension 
balance to test the effect of blood and plasma proteins on 
surfactant. Investigators have tested mixtures of protein 
and surfactant on the surface balance i) using surfactant as 
a subphase solution (Gardner et al~ 1962; Mandelbaum & 
Giammona, 1964; Tierney & Johnson, 1965), ii) by placing the 
mixtures on the surface of subphase solutions with the glass 
rod or droplet techniques (Taylor & Abrams, 1966; Miyahara, 
1969; Tabak & Notter, 1977; this thesis), and iii) using 
protein as the subphase solution with surfactant as the 
surface film (Rufer & Stolz, 1969). In this thesis mixtures 
of protein and surfactant were placed on the surface of a 
saline hypophase solution using the droplet technique. It 
was found that all of the plasma protein fractions, 
fibrinogen, albumin and the globulins, inhibited the 
surfactant from reaching low surface tensions on compression 
of the surface. 
The situation of surfactant inactivation in vivo may be 
represented by the model where both surfactant and protein 
occupy the air-water interface as employed in this 
investigation. Other possibilities include: i) the protein 
might enter the hypophase and have to penetrate the surface 
film of phopholipid, ii) the protein may combine wit~ 
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surfactant precursors (eg tubular myelin) in the hypophase 
and prevent the adsorption of the DPPC to the surface, iii) 
the inflammatory reaction which injures the capillary 
endothelium and the alveolar epithelium may also destroy the 
surfactant with proteases and phospholipases, and iv) in the 
case of large amounts of leak, the edema fluid may displace 
the surfactant from the surface by washing it out of the 
alveoli. 
In this section the possibility was tested that protein 
may enter the hypophase and penetrate a surface film of 
surfactant to prevent the achievement of low surface 
tension. The protein was injected into a saline hypophase 
beneath a preformed surfactant surface film on the surface 
balance. In another model of protein-surfactant 
interaction, a surface film of protein was allowed to form 
from a hypophase solution containing protein before 
surfactant was layered on the surface. 
Methods 
In the first model (Figure 4-7) 1 ml of a 25 mg/ml 
solution of bovine serum albumin (BSA) was injected beneath 
a preformed surface film of surfactant over 1 minute. 
Because the ability of the protein to penetrate the surface 
film might depend on the initial spacing between the 
surfactant molecules, the surface load of surfactant was 
tested at 3.9 ug PL and 7.8 ug PL. This corresponds to an 
2 
area per molecule of 170 angstroms /molecule and 85 
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2 
angstroms /molecule, respectively. These packing densities 
do not approach those in the lung where surface tensions are 
less than 20 mN/m. 
2 
The area per molecule of DPPC at 20 mN/m 
is 45 angstroms /molecule. Hence these spacings should 
adequately test penetration of the surface by the protein. 
The BSA was injected into the hypophase of solution #1 so 
that the final concentration was 1 mg/ml. The BSA was first 
injected into the hypophase solution with no surface film of 
surfactant to test for mixing and to see if the BSA would 
reach the surface. The surface tension at maximum surface 
area was seen to decrease immediately on injection, 
indicating that the BSA had reached the surface immediately. 
When testing for the penetration by the BSA of a preformed 
surfactant surface film, the surface film of surfactant was 
allowed to equilibrate for 3 minutes before injecting the 
BSA into the subphase. Five minutes were then allowed 
before compression was started. 
In the second model (Figure 4-7), a solution of BSA, 1 
mg/ml in solution #1, was used as the hypophase solution. 
After 5 minutes, surfactant was placed on the surface with 
the droplet technique. Compression was started then after 3 
minutes. 
Results and discussion 
The inhibition seen for the model of surfactant l~yered 
onto the subphase of protein was greater than that seen for 
126 
Protein and surfactant in the surface film 
Protein in the subphase beneath the surface film 
Fi gure 4-7 Models of protein-surfactant interaction 
Table 4-4: 
Delta gamma-min, 
mN/m 
surfactant on 
subphase of protein 
protein injected into 
subphase beneath 
surfactant 
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Delta gamma-min for the models 
on the surface balance 
surfactant surface load 
(ug PL) 
3.9 
7 +3 
(n~2) 
2 +0 
(n~2) 
7.8 
11 +3 
(n=2) 
the model of protein injected beneath a preformed surface 
film of surfactant (Table 4-4). This applied to both 
surface loads of surfactant. Low minimum surface tension 
was seen when protein was injected beneath the preformed 
surfactant surface film even with a low surface load of 
surfactant. This suggests that two different mechanisms of 
interaction were involved. 
In the model where surfactant was layered onto the surface 
of a subphase of protein, it was not known that the 
surfactant would form a complete surface monolayer over the 
protein hypophase. It was possible also that the surface 
film would contain both protein and surfactant in the 
expanded phase of the cycle before compression was started. 
The surface tension at maximum surface area of a 7.8 ug PL 
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surfactant load alone on a hypophase of saline was greater 
than that on a hypophase of BSA, approximately 55-60 mN/m vs 
45 mN/m, respectively. The surface tension of the BSA 
hypophase solution at maximum surface area, after a 5 minute 
equilibration time, was also about 45 mN/m. This implied 
that both surfactant and protein coexisted at the surface at 
maximum surface area before compression was started. 
In the surface film of unfolded protein it is likely that 
the form of protein would be hydrophobic, would not easily 
be excluded from the surface, and would compete for surface 
space. This model then, could be considered another test of 
protein and surfactant coexisting or competing at the 
surface, rather than a model to test protein penetration of 
a surfactant surface film. 
When protein was injected into the hypophase beneath the 
preformed surfactant surface films, there was a small 
decrease in surface tension initially at maximum surface 
area before compression was started. This increase in 
surface activity indicated that protein did reach the 
surface. However the surface tensions at minimum surface 
area after compression were low, indicating that the 
surfactant was not inhibited and that the proteins were 
excluded from the surface. Even though the protein reached 
the surface it may not have been able to unfold into a more 
hydrophobic form due to the presence of the lipid at the 
surface. 
The effect of time on the ability of the protein to 
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penetrate a preformed surfactant surface film was studied. 
on a hypophase of solution #1 with surface loads of 
surfactant less than 7.5 ug~ and with waiting times greater 
than 30 minutes, the ability of the surfactant to reach low 
surface tensions was impaired, ie. gamma-min was greater 
than 10 mN/m. Perhaps the longer equilibrium times 
predisposed to oxidation of the phospholipid. In tests of 
penetration of the surfactant surface layer, BSA was 
injected into a hypophase of solution #1 to a final 
concentration of 1 mg/ml beneath a surfactant surface layer 
with 7.5 ug PL which had been allowed to equilibrate for 3 
minutes. 
started. 
30 minutes were allowed before compression was 
There was no change in minimum surface tension. 
Gamma-min was less than 4 mN/m, delta gamma-min=O, n=2. 
In summary, one model suggested that protein entering the 
hypophase beneath a surfactant surface film would be easily 
excluded from the surface. A second model testing protein 
and surfactant competition for surface space also exhibited 
surfactant inhibition. 
4.2.4 Tests on the pulsating bubble apparatus 
The pulsating bubble apparatus~ after Enhorning (l977a), 
may also give clues to the mechanism of inhibition. In this 
instrument an air bubble is created in a fluid-filled 
chamber by the application of negative pressure to imitate 
alveolar opening in the lung. The surface tension at the 
air-water interface is reflected by the pressure required to 
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keep the bubble open. The change in surface tension on 
opening the bubble would indicate the rate at which the 
surface active molecules were entering the surface film 
(adsorption to the interface) from the subphase. Changes in 
this rate in the presence of added protein might indicate 
that the protein would affect the rate of insertion of the 
DPPC into the surface. 
The bubble can also be pulsated, the effect of which is 
compression and expansion of the surface area (dynamic 
alveolar model). The rate at which minimum surface tension 
was reached after pulsation was started would suggest the 
rate at which protein or components other than DPPC might be 
excluded from the surface film on compression. 
It was felt that this instrument would provide good models 
for tests of selective insertion and exclusion of DPPC into 
and from the air-water interface using a mixture of 
surfactant and protein. 
In preliminary tests however, the pig lung surfactant 
preparations did not have consistent rates of opening 
surface tensions or consistent rates of reaching minimum 
surface tensions on pulsation of the bubble. The time 
elapsed from the opening of the bubble to an opening 
pressure of 1 em H 0 ranged from 73 to 136 seconds (0.65 ug 
2 
PL/ul) (Figure 4-9). Similar variability was seen in the 
initial rate of change of opening pressure or in the time 
taken to reach any given opening pressure. The time elapsed 
from beginning pulsation to an opening pressure of 0 .• 25 em 
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air 
fluid-filled 
chamber 
F igure 4-8 The dynamic alveolar model 
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H 0 ranged from 1.5 sec (first cycle) to 16 minutes (1.3 ug 
2 
PL/ul). Tests of surfactant-protein interaction were not 
done at this time. 
0 
2. 5 
Figure 4-9 
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time . 
/initial rate 
I 
I 
time to 1 em H 2 o 
bubble opened to maximum size 
minimum bubble size 
maximum bubble size 
pulsator on 
Examples of tracings from the pulsating 
bubble apparatus 
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Chapter 5 
Summary and biologic relevance 
The relevance of testing protein-surfactant mixtures on 
the surface balance has been discussed in relation to 
surfactant dysfunction in RDS and in particular the RDS 
following CPB. In RDS an acute lung injury produces leaking 
blood-air membranes through which plasma constituents enter 
the alveoli. This thesis addressed the hypothesis that 
plasma constituents could inhibit surfactant from proper 
function. 
Adult respiratory distress syndrome is a cause of 
significant morbidity and mortality in today's medicine. 
Its incidence is increased in the setting of trauma. This 
condition became well recognized during the Viet Nam War 
when improved skill in resuscitation prolonged 
survival from injuries which would have previously been 
immediately fatal. However with this prolonged 
survival, ARDS became a major cause of late fatality. Today 
ARDS is a significant cause of mortality in the victims of 
motor vehicle accidents. The fatality rate remains at 50% 
once ARDS develops despite improved critical care medicine. 
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Much research has been done on this prevalent disease. 
From a pathophysiologic viewpoint, most studies have 
addressed the mechanisms of acute injury to the lung and 
there is a tremendous literature concerning the possible 
injurious agents, eg. complement, leukocyte products, 
platelet products, fibrin degradation products, etc. In 
contrast, studies on surfactant dysfunction have been less 
extensively investigated. 
Surfactant dysfunction is an important result of the acute 
lung injury. Dysfunctional surfactant would contribute to 
the clinical problems of atelectasis and pulmonary edema 
resulting in poor gas exchange. It was important and 
logical to consider the possibility that plasma constituents 
which are known to enter the airspaces through leaking 
blood-air membranes produced by the acute lung injury, might 
inhibit surfactant from proper function. 
Cardiopulmonary bypass is a known etiologic agent of acute 
lung injury, and although the incidence of RDS following 
operations involving CPB is small in elective adult cardiac 
surgery today, RDS remains a significant complication in 
pediatric cases and in cases involving prolonged bypass. 
CPB provided a setting where the inflammatory response 
induced in the blood might produce or increase levels of 
potential circulating surfactant inhibitors. The induced 
inflammatory response is a mechanism whereby blood-air 
membranes could be injured, resulting in leaking membranes 
and entry of plasma constituents into the alveoli. The 
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pathophysiologic characteristics of acute lung injury and 
surfactant dysfunction~ and the clinical characteristics of 
RDS following CPB are similar to those of ARDS. CPB is 
included in the long list of etiologic factors of ARDS. 
The literature presented an inconsistent view of 
surfactant inhibition by blood and plasma proteins. This 
inconsistency was also seen in studies of the effect of CPB 
on surfactant inhbitors in blood. Some of the inconsistency 
may have resulted from variation in the methods of testing 
surfactant-potential inhibitor mixtures on the surface 
balance since different mechanisms of interaction might 
provide different results. No previous investigation had 
studied human subjects undergoing CPB. 
The task of studying surfactant inhibition in this thesis 
involved defining one mechanism of surfactant-potential 
inhibitor interaction, then testing for the presence of 
potential inhibitors using this assay. 
The assay used was a model of protein-surfactant 
interaction where both protein and surfactant would coexist 
at the surface. Mixtures of protein and surfactant were 
placed on the surface of a hypophase solution of saline. 
The attainment of low surface tension on compression of the 
surface was used as an indicator of surfactant function. 
Tests to determine conditions of optimum surface balance 
function were performed. Test conditions were precisely 
defined in consideration of the variability in the 
literature and in contrast to some previous literature 
cited. 
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The plasma from normal individuals was found to inhibit 
surfactant. In a study controlled with prebypass and 
postbypass samples, CPB did not increase this inhibition in 
adult patients or in child patients. Surfactant inhibition 
by plasma taken from child patients was not greater than 
that taken from adults. Tests of surfactant inhibition by 
plasma in this assay did not provide reasons for the 
increased incidence of postpump lung dysfunction seen in 
children or in prolonged bypass. 
Thus the data were consistent with the view that modern 
CPB itself does not produce surfactant inhibitors in plasma 
or increase the levels of inhibitors in plasma. Of the 
patients studied only one child developed RDS as a 
complication of CPB. The possibility that additional 
inhibitors may be produced in the group of patients who 
subsequently develop RDS was not studied. One reason is 
that the frequency of RDS following CPB in elective adult 
cardiac surgery is less than 2%. 
The data were consistent with the possibility that plasma 
components entering the alveoli through leaking lung 
membranes could inhibit surfactant from proper function. In 
this setting the degree of injury to the blood-air membranes 
would determine the extent of plasma leakage and the degree 
of surfactant dysfunction. The increased incidence of 
postpump lung dysfunction seen in children undergoing CPB 
and in prolonged bypass would then possibly depend on an 
increased extent of injury to the lung membranes as a result 
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of the CPB or an increased susceptibility of the lung to 
injury. For example, prolonged bypass may induce a greater 
inflammatory response in the blood, and children may have 
more fragile lungs. 
The raised minimum surface tensions of 20-30 mN/m of the 
protein-surfactant mixtures seen in the tests of this thesis 
are similar to the minimum surface tensions seen in tests of 
lung washings and extracts of lung minces from patients with 
RDS in adults and infants. In this range of surface tension 
there is the clinical picture of lung collapse and alveolar 
edema. In contrast, alveolar surface tension has been 
measured in vivo in normal cat lungs at 40% total lung 
capacity as less than 1 mN/m (Schurch, 1982). 
In a proposed mechanism of inhibition, when both protein 
and surfactant exist at the surface, the protein was not 
excluded from the surface film hence preventing the DPPC 
component of surfactant from achieving high packing density 
and low surface tension. No specific surfactant inhibitor 
was suggested by the data. It seemed unlikely that plasma 
components other than proteins would contribute to 
surfactant inhibition. The plasma protein fractions 
fibrinogen, albumin and globulins were all seen to inhibit 
surfactant. 
Other models of protein-surfactant interaction on the 
surface balance were studied. Surfactant layered on a 
hypophase of protein likely represented an alternate model 
of protein and surfactant at the surface whereas protein 
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injected beneath a preformed surfactant surface film tested 
penetration of the surfactant surface film by the protein. 
While protein and surfactant at the air-water interface in 
vivo would result in surfactant dysfunction, the actual 
mechanism whereby plasma protein would reach the surface to 
interact with the surfactant is unknown. 
Nechanisms of the effect of plasma protein on surfactant 
may possibly be investigated further using the pulsating 
bubble apparatus. Consideration of the possibility that 
surfactant inhibitors produced by the acute lung 
inflammation and injury, and which might be local to the 
lung (ie. not circulating in the blood) is not without 
merit. 
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Appendix A 
Methods and Protocols 
A.1 Solutions for BAL protocols 
These solutions were given in the paper by King & Clements 
(1972). The solutions all contained .005M TRAM with pH 
adjusted to 7.35 with concentrated HCl. 
NaCl NaBr MgCl CaCl 
2 2 
Solution Ill : . 15M 0 .003M .003M 
Solution 112: .015M .6M .004H • 0 0 4~1 
Solution 113: .15M 1.4M .031M .031M 
Solution 114 : .15M 1.64M .035N .035M 
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A.2 Modification of the Yu et al (1983) protocol for 
bronchoalveolar lavage fluid (BAL) 
All centrifugations were done at 4 degrees c. 
1. The BAL was centrifuged at 800 gav for 10 min 
(RC-3 Sorvall; Sorvall rotor HG-4L; 1685 rpm). 
2. The supernatant from (1) was centrifuged at 8000 gav 
for 60 min (Beckman J2-21; JA-10 rotor; 6800 rpm). 
3. The pellet from (2) was resuspended in solution #1, 
then dialysed (12,000 MW exclusion membrane) against 
H 0 for 48 hrs (5 changes in bath, 4 degrees C). 
2 
4. The non-diffusable material was lyophilized and 
stored at -20 degrees C. 
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A.3 Modification of the King & Clements (1972) protocol for 
BAL 
All centrifugations were done at 4 degrees C. 
1. The BAL was centrifuged at 800 gav for 10 min 
(RC-3 Sorvall; Sorvall rotor HG-4L; 1685 rpm). 
2. The supernatant from (1) was centrifuged at 
65,900 gav for 90 min 
(Beckman L3-50; 42.1 rotor; 31,000 rpm). 
3. The pellet from (2) was resuspended in solution #4 
(78 ml) and centrifuged at 81,500 gav for 15 hrs 
(Beckman L5-50B; SW 28 rotor; 24,500 rpm). 
4. The floating white pellicle from (3) was removed with 
spatula and pasteur pipette. It was resuspended in 
solution #1 and centrifuged at 65,900 gav for 2 hrs 
(Beckman L3-50; 60 Ti rotor; 31,000 rpm). 
5. The pellet from (4) was resuspended in solution #3 
(78 ml) and left to equilibrate overnight. 
6. A continuous density gradient using the suspension 
from (5) and an equal volume of solution #2 was made, 
then centrifuged at 81,500 gav for 15 hrs 
(Beckman L5-50B, SW 28 rotor; 24,500 rpm). 
7. The band of white particles about one-third of the 
way up from the bottom of the centrifuge tubes was 
aspirated (about 2 ml). The aspirate was diluted with 
solution #1 (30 ml) and centrifuged at 65,900 gav for 
2 hrs (Beckman L5-50B; 60 Ti rotor; 31,000 rpm). 
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8. The pellet from (7) was resuspended in solution #3 
(78 ml) and centrifuged at 65,900 gav for 15 hrs 
(Beckman L5-50B; SW 28 rotor; 24,500 rpm). 
9. The pellicle from (8) was resuspended in H 0 and 
2 
centrifuged at 65,900 gav for 2 hrs (Beckman L5-50B; 
60 Ti rotor; 31,000 rpm). 
10. The pellet from (9) was resuspended in solution #l 
and dialysed against H 0 for 48 hrs, with 5 
2 
changes in water bath, at 4 degrees c. 
11. The non-diffusable material was lyophilized and 
stored at -20 degrees C. 
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A.4 Modification of the Shelley et al (1977) protocol for 
BAL 
All centrifugations were done at 4 degrees C. 
1 • The BAL was centrifuged at 800 gav for 10 min 
(RC-3 Sorvall; Sorvall rotor HG-4L; 1685 rpm). 
2. The supernatant from (1) was centrifuged at 
8000 gav for 60 min 
(Beckman J2-21; JA-10 rotor; 6800 rpm). 
3. The pellet from (2) was resuspended in solution #4 
and centrifuged at 81,500 gav overnight 
(Beckman L5-50B; SW 28 rotor; 24,500 rpm). 
4. The pellicle from (3) floating on top was removed 
with a spatula and a pipette and resuspended in 
solution #1. It was then centrifuged at 65,900 gav 
for 2 hrs (Beckman L3-50; 60 Ti rotor; 31,000 rpm). 
5. The pellet from (4) was resuspended in 20 ml of a 
16 g/dl NaBr solution. A discontinuous density gradient 
was formed by layering on 32 ml of a 13 g/dl NaBr 
solution, then 8 ml of a 0.9 g/dl NaCl solution. The 
gradient was then centrifuged at 81,500 gav for 3 hrs 
(Beckman L5-50B; SW 28 rotor; 24,500 rpm). 
6. The pellicle from (5) formed at the interface between 
the 13% NaBr and the saline was removed with spatula 
and pipette. 
centrifuged 
It was resuspended in solution #1 and 
at 65,900 gav for 90 min 
(Beckman L5-50B; 60 Ti rotor; 31,000 rpm). 
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7. The pellet from (6) was resuspended in solution #1 and 
dialysed against H 0 (12,000 MW exclusion membrane) 
2 
for 48 hrs, with 5 changes in water bath, 
at 4 degrees C. 
8. The non-diffusable material was lyophilized and 
stored at -20 degrees c. 
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A.5 Our protocol for preparation of surfactant from BAL 
All centrifugations were done at 4 degrees C. 
1. The BAL was centrifuged at 800 gav for 10 min 
(RC-3 Sorvall; Sorvall rotor HG-4L; 1685 rpm). 
2. The supernatant from (1) was centrifuged at 
8,000 gav for 60 min 
(Beckman L3-50; 42.1 rotor; 6800 rpm). 
3. The pellet from (2) was resuspended in solution #4 
and centrifuged at 81,500 gav overnight 
(Beckman L5-50B; SW 28 rotor; 24,500 rpm). 
4. The pellicle from (3) floating on top was removed 
with a spatula and a pipette and resuspended in 
solution #1. It was then centrifuged at 65,900 gav 
for 2 hrs (Beckman L3-50; 60 Ti rotor; 31,000 rpm). 
5. The pellet from (4) was resuspended in solution #1 
and dialysed (12,000 MW exclusion membrane) against 
H 0 for 48 hrs with 5 changes in water bath, 
2 
at 4 degrees C. 
6. The non-diffusable material was lyophilized and 
stored at -20 degrees C. 
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A.6 Preparation of surfactant suspensions 
The lyophilized pig lung surfactant had been stored at -20 
degrees C. Suspensions of 2 mg/ml of surfactant in solution 
#1 were made for testing on the surface balance. The 
lyophilized material was suspended by stirring with a glass 
rod, vortexing, and sonicating (3 bursts of 100 watts of 15 
sec duration each; Sonifer Cell Disruptor, Ultrasonics; 
microprobe with 13 mm horn and 3.2 mm tip). The material 
was kept cool in an ice bath between sonications. The 
suspensions of surfactant were divided into 0.5 ml aliquots 
and stored in glass vials at -20 degrees C. 
Tests of surfactant function were made on the surface 
balance using thawed aliquots of the surfactant suspensions. 
All comparative tests of surfactant function were performed 
using the same batch of lyophilized surfactant prepared in 
one processing protocol, harvest date 1/8. 
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A.7 Phosphate determination by a modification of the method 
of Bartlett (1959) 
Materials 
1. chromic acid-washed glass tubes 
2. 70% perchloric acid 
3. ANSA 
4. molybdate 
5. antibumping granules 
Methods 
1. Add antibumping granules, 50 ul of 2 mg/ml 
surfactant, 1 ml of perchloric acid 
2. Boil for 10 minutes or until clear 
3. Add 8.0 ml H 0, 0.5 ml molybdate, 0.5 ml ANSA 
2 
4. Vortex 
5. Standard: 2 ml of 2 ug phosphorus/ml standard 
solution, 1.0 ml of perchloric acid, 6 ml of 
H 0, 0.5 ml molybdate, 0.5 ml ANSA 
2 
6. Immerse standard and samples in boiling water bath 
for 12 minutes 
7. Read optical density at 815 nm 
8. Phospholipid concentration estimated by multiplying 
the phosphate concentration by 25 
9. Linearity of the test was determined using standard 
phosphate solutions 
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A.8 Biuret protein determination after Gornall et al (1949) 
Materials 
Biuret reagent 
1.5 g CuSO .SH 0. 
4 2 
Dissolve in 500 ml H 0 
2 
Add 6 g NaK Tartarate 
Add with constant swirling, 300 ml of 10% NaOH 
Dilute to 1 litre and store in dark bottle 
5% deoxycholic acid (DOC) 
standard bovine serum albumin solution (BSA) - 5 rug/ml; 
crystalline BSA from Sigma catalog no. A-7906, 
lot 53F-0256, nb. H 0 content 5.6% 
2 
Methods 
1 • Size of test sample = so ul 
2. Add 0.2 ml of 5% DOC, 0.75 ml H 0, 
2 
4.0 ml Biuret reagent 
3. Vortex, and let stand for 30 min before reading 
optical density 
4. Standard curve: 4.0 ml of Biuret reagent, 0.2 ml DOC, 
various amounts of standard protein solution 
0.2, 0.4, 0.6, 0.8 1.0 ml with corresponding amount of 
H 0 to make up 5.0 ml in total 
2 
5. Control: 4.0 ml Biuret reagent, 1.0 ml H 0 
2 
6. Read optical density at 550 nm 
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A.9 Polyacrylamide gel electrophoresis~ W.Davidson~ personal 
communication 
Materials 
Separating gel 60 ml 
10 ml Tris-sulfate pH 9.0~ 1.5 M Tris~ 
titrated with sulfuric acid 
20 ml 0.2% ammonium persulfate 
14 ml H 0 
2 
16 ml 30% acrylamide (0.8% Bis) 
4 drops TeQed 
Stacking gel 10 ml 
Methods 
1.25 ml Tris-sulfate pH 7.4~ 0.5 M Tris 
5.0 ml 0.2% ammonium persulfate 
2.5 ml H 0 
2 
1.25 ml 30% acrylamide (0.8% Bis) 
2 drops Temed 
A mold for shaping the slab gel was made using two glass 
plates (20.7 x 26.0 em) separated with plastic borders (PVC 
plastic, 1.6 mm thick)~ sealed with high pressure vacuum 
grease and clamped with large spring-type paper clips. The 
separating gel (approximately 20 em in length) was poured 
into the mold leaving room for the stacking gel at the top 
(approximately 5 em from the top edge of the glass). The 
separating gel was covered with isopropanol to create a 
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smooth surface. At least 4-5 hours were allowed for 
polymerization. The propanol was poured off. A plastic 
comb (12 tooth PVC comb with tooth measurements 0.65 x 1.9 
em) was inserted above the separating gel as a template for 
the stacking gel. The stacking gel was poured under the 
comb and was allowed to polymerize for 1-2 hrs. The comb 
was removed to expose the wells (0.65 x 1.9 em) into which 
the samples were placed. The samples were mixed with 50% 
glycerol (sample:glycerol, 3:1, v:v) to settle the sample at 
the bottom of the well. The samples were inserted to a 
maximum of 30 ul per well. Bromphenol blue was used in the 
side wells as a migration marker. The gel was run at 
constant current, 10 rnA per gel with the voltage under 200 
v. to avoid heat denaturation of the proteins. The running 
time was about 10-12 hrs. The gel was then removed from 
between the glass plates and handled with gloves (to avoid 
protein contamination from the fingers). Coomassie brilliant 
blue was used to stain the gel for 1 hr.(0.2 g Coomassie 
G250, 500 ml H 0, 25 ml 70% perchloric acid). The gel was 
2 
then destained and fixed with 3-4 rinses of 7% glacial 
acetic acid over 48 hrs. 
0 
b uffer 
buffer 
0 
figure A-1 
1 7 6 
stacking gel 
Apparatus for polyacrylamide gel 
electrophoresis 
separating gel 
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A.10 Polyethylene glycol (PEG) fractionation of plasma 
proteins 
Ikegami et al (1983); Polson et al (1964) 
Materials 
PEG average MW 3350, Sigma P-3640 Lot 43F0292 
0.02 M monobasic phosphate and NaOH buffer pH 7.0 
titrated with concentrated HCl 
Methods 
Plasma was prepared with heparin. It was diluted with the 
phosphate buffer to 0.4 g/dl (5 ml plasma, 95 ml buffer). 
PEG was added slowly with stirring at room temperature to 
17 g/dl to yield an opaque white liquid. Equilibration was 
allowed over 20 minutes before centrifugation at 10,000 gav 
for 15 min at 21 degrees C (Beckman L-50B centrifuge, 60 Ti 
rotor, 11,800 rpm). This yielded a clear supernatant (PEG 
17%) and a white precipitate (expected to contain fibrinogen 
and the globulins as the major components). 
PEG was added slowly to the supernatant from (2) to 25 
gm%, (assume volume of solid PEG of 0.66 ml/g). The pH was 
adjusted to 5.4 with concentrated HCl to yield an opaque 
yellowish liquid. After equilibration for 20 min, the 
liquid was centrifuged at 10,000 gav for 15 min at 21 
degrees C. This yielded a clear supernatant and a white 
precipitate (expected to contain albumin). 
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PEG was added slowly to the supernatant from (3) to 50%, 
followed by an equilibration time of 20 min. The liquid was 
centrifuged at 10,000 gav for 15 min. at 21 degrees C. No 
precipitate was observed by visual inspection, although the 
fraction was treated as if there was a precipitate. This is 
the fraction in which the inhibitor of Ikegami and Jobe 
might be expected. 
All of the precipitates from the 3 fractions were 
resuspended in solution #1. The PEG 25% fraction required 
adjustment of the pH back to 7.0 with NaOH before it 
dissolved. With no observable precipitate in the 50% 
fraction, this fraction was collected by rinsing the inside 
walls of the centrifuge tubes with solution #1. Minimum 
amounts of solution #1 were used to redissolve the proteins 
so that the protein concentration would be comparable to 
plasma protein concentrations. This was desirable for 
testing on the surface balance since too low a protein 
concentration would require high volumes of solution to test 
equivalent amounts of protein on the surface. 
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A.11 Refractive index (RI) tables for solutions of bovine 
serum albumin (BSA) and polyethylene glycol (PEG) 
Table A-1: RI vs [BSA] 
RI 
-.3 
-.1 
0 
0.4 
1.2 
2. 7 
5.8 
Table A-2: 
RI 
1. 9 
3.3 
4.2 
7.8 
16.2 
21.3 
39.5 
Table A-3: 
RI 
3.2 
7.5 
15.0 
18.9 
34.6 
[BSA]mg/ml 
0.96 
1.90 
3.85 
7.70 
15.40 
30.80 
61.60 
RI vs [PEG], [BSA] 
[PEG]g/dl 
2.5 
4.5 
5.0 
10.0 
20.0 
25.0 
50.0 
0 mg/ml 
Rl vs [PEG], [BSA] = 6.16 mg/ml 
[PEG]g/dl 
4.5 
9.0 
18.0 
22.5 
45.0 
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Table A-4: RI vs [PEG], [BSA] = 10.3 mg/ml 
Rl 
3.3 
7. 3 
14.6 
18.4 
34.8 
[PEG]g/d1 
4.3 
8.6 
17.1 
21.4 
42.9 
Table A-5: RI vs [PEG], [BSA) = 20.5 mg/m1 
RI 
4.3 
4.7 
7. 1 
12.8 
15. 8 
29.6 
Table A-6: 
Rl 
4.5 
4.8 
6.8 
11.0 
13.4 
22.7 
Table A-7: 
RI 
5.0 
6.5 
9.4 
11.2 
18.0 
[PEG]g/dl 
3.0 
3.3 
6.7 
13.3 
16.7 
33.3 
RI vs [PEG], [BSA] = 30.8 mg/ml 
[PEG]g/dl 
2.3 
2~5 
5.0 
10.0 
12.5 
25.0 
RI vs [PEG], [BSA] = 41.1 mg/m1 
[PEG]g/d1 
1. 7 
3. 3 
6.7 
8.3 
16.7 
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Table A-8: RI vs [BSA], taken from the plots of 
RI 
0.62 
0.37 
1.76 
2.87 
3.66 
Table A-9: 
the data, RI vs [PEG] for various [BSA] 
at the y-intercepts 
[BSA]mg/ml 
6.16 
10.30 
20.50 
30.80 
41.10 
Delta gamma-min vs [PEG/PL], 
sam F load = 7.8 ug PL 
delta gamma-min 
(mN/m) 
[PEG/PL] 
(ug/ug) 
3.4 
2.3 
3.5 
5.8 
3.4 
5.8 
8.0 
14.9 
15.8 
18.4 
1.3 
2.6 
6.4 
12.8 
12.8 
16.0 
32.1 
32.1 
51.3 
64.1 
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A.12 Ethanol precipitation of the PEG fractions using the 
Cohn method 
Cohn et al (1950); Edsall & Anson (1947) 
Materials 
1. Acetate buffer pH 4.0 (180 ml 0.2M NaOAc, 820 ml 
0.2M HOAc) 
Methods 
All work was done at 4 degrees C. All solutions, glassware 
and centrifuge tubes and rotor were prechilled. The 
temperature of precipitation should be 0 to -5 degrees c. 
Each PEG fraction precipitate was resuspended in 10 ml of 
solution #1 and chilled. 
Redistilled 95% ethanol was added drop by drop with a 
pasteur pipette. The solutions were kept in an ice-water 
bath. 
To the solution containing the PEG 17% precipitate, 
ethanol was added to 25% v:v (3.5 ml). This was expected to 
precipitate fibrinogen and the gamma and beta globulins. 
To the solution containing the PEG 25% precipitate, 
ethanol was added to 40% v:v (7.0 ml), then the pH adjusted 
to 4.8 with the acetate buffer (about 0.63 ml). The pH was 
checked by taking up 0.2 ml of the ethanol-protein solution 
in 9 volumes of water (1.8 ml) in order to dilute the 
ethanol for reading the pH with a glass electrode. 
To the solution containing the PEG SO% precipitate, 
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ethanol was added to 40% v:v (7.0 ml), then the pH adjusted 
to 4.8 with the acetate buffer. 
The fractions were centrifuged at 10,000 gav, at 
temperature -5 degrees C, for 15 minutes (Beckman L3-50, 60 
Ti rotor, 11,800 rpm). About 10 minutes of equilibration 
time elapsed from the adding of the ethanol and adjustment 
of the pH to the time of centrifugation. 
The precipitates were resuspended in 1 ml of solution #1, 
then dialysed with an 8,000 MW membrane in solution #1 at 4 
degrees C overnight. The microdialysis method of Lau & 
Fujitaki (1981) was used. This consisted of placing the 
sample in a 1.5 ml plastic ''Eppendorf" centrifuge tube 
covered by the dialysis membrane which was tied in place 
with a silk thread (Figure A-2). The tube was taped to the 
side of a 600 ml glass beaker. The dialysis bath of 500 ml 
was stirred constantly by magnetic stirrer. 
air 
bath 
figure A-2 
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Method for microdialysis 
sample 
silk thread 
dialysis membrane 
A.l3 Materials and equipment 
acetid acid (glacial) 
acrylamide 
albumin (human) 
ammonium molybdate 
ammonium persulfate 
ANSA 
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(1-amino-2-naphthol-4-sulfonic 
antibumping granules 
BIS 
(NN-methylene-bis-acrylamide) 
bromphenol blue 
BSA (bovine serum albumin) 
CaCl (dihydrate) 
2 
chloroform 
citric acid 
(trisodium salt dihydrate) 
Coomassie brilliant blue G250 
CuSO (pentahydrate) 
4 
deoxycholic acid (sodium salt) 
dialysis membrane 
DPPC 
DSPC 
electrophoresis power supply 
ethanol (95% redistilled) 
fibrinogen (human) 
freeze-dryer (lyophilizer) 
globulins (human)-gamma 
and beta 
-alpha 
HCl (37%) 
Supplier, catalog 
number, 
lot number 
Fisher A-38 
BioRad 161-0107 
Red Cross product 
Fisher A674 
BioRad 161-0700 
Sigma A0505 
acid) 
BDH 2189 
BioRad 161-0200 
BioRad 161-0404 
Sigma A7906 
lot 53-F-0256 
Sigma C-3881 
Fisher C-605 
Sigma C7254 
BioRad 161-0406 
Sigma C7631 
Sigma D6750 
Fisher 8-667B 
Sigma P6267 
Sigma P1138 
Hoefer Scientific 
Instruments PS1200 
Consolidated 
Alcohols, Toronto 
Sigma F3879 
lot 81F-9365 
Labconco 
Sigma G2388 
lot 93F-9365 
Sigma G2011 
lot llF-9317 
CanLab C9800-10 
heparin 
(porcine intestinal mucosa) 
hexane (pesticide grade) 
isopropanol 
LaCl (7 H20) 
3 
methanol 
MgCl 
2 
NaBr 
NaCl 
NaH PO 
2 4 
NaOH 
NaK tartarate 
perchloric acid (70%) 
polyethylene glycol 
proteinase K 
refractometer 
sonicator 
spectrophotometer 
sucrose 
sulfuric acid 
surfactometer 
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Temed (tetramethylene diamine) 
THAM 
Organon 
Fisher H-300 
Fisher A-416B 
Sigma L4131 
Fisher A-936 
Fisher M-33 
Fisher S-255 
Fisher S-271B 
Sigma S0751 
Fisher S-318B 
Sigma S-2377 
Fisher A-229 
Sigma P3640 
Sigma P-0390 
lot 14F-0142 
Fisher Scientific 
Sonifer Cell Disruptor 
Heat Systems-Ultrasonics 
Unicam (SP500 Series 2) 
Sigma S9378 
Fisher A-300 
Kimray-Greenfield 
(surface balance) 
Surfactometer 
International 
(pulsating bubble 
apparatus) 
BioRad 161-0800 
Fisher T-395 
(tris hydroxymethyl aminomethane) 
vortex Fisher 




